Skip to main content

Talk Bio

Actionable Insights Powered by AI

Search This Blog

About

Posts

Eli Lilly Boosts Orforglipron GLP-1 Pill Production with Major Investments in China and Inventory Buildup

on March 11, 2026

boost China Eli GLP-1 pill Investments orforglipron production South Korea

+

Eli Lilly is ramping up production of its GLP-1 pill orforglipron, with pre-launch inventory capitalized at $1.5 billion as of its 2025 annual report to avoid past shortages 2 . Eli Lilly plans to invest $3 billion in China and submitted a marketing application for orforglipron to China's drug regulator at the end of 2025 5 . Eli Lilly has built nearly $550 million worth of orforglipron-related inventory by February 2025 and is constructing four new US manufacturing facilities as part of a $27 billion investment for weight loss therapies 2 . Orforglipron outperformed Novo Nordisk's oral semaglutide in trials for blood sugar, weight loss, and heart health, with potential US approval as early as Q2 2026 1 4 . No specific $500M pledge to South Korea is detailed in recent reports; focus remains on US stockpiling, China investment, and global production strategies 1 2 5 . Sources: 1. https://www.businessinsider.com/eli-lillys-orforglipron-beats-novo-nordisk-glp1-pill-in-...

Get link
Facebook
X
Pinterest
Email
Other Apps

Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis

on March 11, 2026

Amicus Therapeutics ClinVar Fabry Disease gamma-linolenic acid gene variants genetic diagnosis Genomenon GLA Mastermind Platform

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Breakout Ventures Closes $114M Fund III for AI-Driven Early-Stage Science and Biotech Startups

on March 11, 2026

Breakout Ventures early-stage Fund III methionine seed investments

+

Get link
Facebook
X
Pinterest
Email
Other Apps

BioNTech Founders Ugur Sahin and Özlem Türeci to Depart and Launch New mRNA Venture

on March 11, 2026

BioNTech RNA, Messenger Spinout Ugur Sahin

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board

on March 11, 2026

Autoimmune Diseases Biological Factors Drug Discovery H. Martin Seidel , Odyssey Therapeutics Scientific Advisory Board

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Dianthus Therapeutics Announces Proposed $400 Million Underwritten Public Offering (Upsized from Initial Plans)

on March 11, 2026

Autoimmune Diseases Dianthus Therapeutics DNTH public entity underwritten

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Biopharma Bites: Breakout Ventures' $114M AI Fund, Amid Funding Shifts

on March 11, 2026

AI biotech biopharma Breakout Ventures early-stage Funding Funds News [Publication Type]

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Rob Pinataro Served as CEO of Payspan During Zelis Acquisition in 2022

on March 11, 2026

acquisition CEO Health Data Innovations healthcare payments Payspan Rob Pinataro Zelis

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Vertex's Povetacicept Clears Phase 3 Milestone in IgA Nephropathy: Blockbuster Potential Ahead?

on March 10, 2026

Approved IGA Glomerulonephritis Kidney Diseases Phase 3 trial povetacicept Proteinuria United States Food and Drug Administration

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Kainova Therapeutics Announces Positive Phase I Results for DT-9081 in Advanced Solid Tumors

on March 10, 2026

Clinical Research DT-9081 EP4 receptor antagonist EPRAD Kainova Therapeutics Phase I Solid Neoplasm

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Federated AI Advances in Binding Affinity and ADMET Prediction for Drug Discovery

on March 09, 2026

ADMET Apheris ADMET Network binding affinity Drug Discovery Federated AI OpenFold3 Prediction

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Xenon Pharmaceuticals' Azetukalner Achieves Phase 3 Success in Epilepsy Trial, Boosting Blockbuster Potential

on March 09, 2026

azetukalner Epilepsy focal onset seizures NDA Phase 3 United States Food and Drug Administration Xenon Pharmaceuticals '

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Roche's Giredestrant Fails Primary Endpoint in Phase 3 Breast Cancer Trial

on March 09, 2026

Drops - Drug Form giredestrant Ibrance Malignant neoplasm of breast persevERA Phase 3 Clinical Trials Roche (company)

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Archive

March 202653
February 2026175
January 2026261
December 2025151
November 2025147
October 2025222
September 2025190
August 2025161
July 2025130
June 2025159

May 2025174
April 2025191
March 2025205
February 2025198
January 202539

Show more Show less

Tags

United States Food and Drug Administration Clinical Trials Approved Obesity gene therapy Neoplasms Vaccines Glucagon-Like Peptide 1 Investments Eli Lilly

Artificial Intelligence Drug Industry Pfizer Market layoffs AstraZeneca Infrequent Roche (company) sanofi Biological Factors China Pharma Novartis Merck Acquisition Autoimmune Diseases Drug Discovery manufacturing Leadership Transplant Registry Unified Management Program restructuring Cell Therapy Nordisk COVID19 (disease) drug price Policy SmithKline Beecham Drug Development Phase 3 CEO Biotechnology CHARGE Syndrome Inhibitor U.S. expansion Safety Wegovy Eli Centers for Disease Control and Prevention (U.S.) Industry IPO United States Biopharma Funding Muscular Dystrophy, Duchenne semaglutide Antibody-Drug Conjugates Appointments acquisition eli lilly Precision Medicine R&D Drug Approval Overall Survival Weight Loss Zepbound AbbVie Immunology Novo Nordisk Partnership Prices Sales - occupational activity Alzheimer 's disease Changing Keytruda Phase 3 Clinical Trials Administration occupational activities Elevidys Health care facility Immunotherapy Regeneron biotech Malignant neoplasm of breast Staff therapeutic autologous dendritic cells Collaboration Moderna Myers Oral cavity RFK Jr. Solid Neoplasm Cancer Therapeutic Procedure Dosage Forms Effectiveness Non-Small Cell Lung Carcinoma Weight-Loss Agents innovation public health medicine (field) Amgen Antibodies Board of Directors UK financial results milestone payments rejection CAR-T Progression-Free Survival Schizophrenia Trump administration 2025 ACIP Antibodies, Bispecific BioNTech Biological Markers Clinical Research Biogen M&A Malignant neoplasm of lung Multiple Myeloma Phase 2 trial Bayer Financial cost Growth Metsera clinical development clinical trial failure squibb trends qualifier Accelerated Biological Science Disciplines Gene Modification Phase 3 Trial earnings Advisory Committees Cardiovascular Diseases Medicare NIH Mouse PDUFA Series Biosimilars Clustered Regularly Interspaced Short Palindromic Repeats Johnson & Johnson Monoclonal Antibodies Q3 genentech platform EU J&J MASH Phase 2 Clinical Trials Study on Hold competition concerns dosing methionine pharmaceutical manufacturing pipeline production research Diabetes Failure (biologic function) Gilead Gilead Sciences Ozempic RFK gene Radiopharmaceuticals AI-driven Biosciences Deferred Discontinuation (procedure) Health Policy Legal patent Medicaid Metabolic Diseases Ophthalmology specialty Programs - Publication Format RNA Robert F. Kennedy Senate Takeda government optimization supply chain venture capital Capital Epilepsy Evaluation HHS Hims Malignant neoplasm of prostate Medical Devices Nasdaq Phase III Pricing RNA Interference Rare Diseases Small cell carcinoma of lung TNFRSF19 gene licensing agreement net loss pharmaceutical tariffs regulatory Agonist Alopecia Amyotrophic Lateral Sclerosis Autoimmune Bispecific Child Dupixent Endpoints Phase 3 trials Response process Transition Mutation cost-cutting development aspects federal in vivo leadership change orforglipron royalties venture AI drug discovery Adverse event Advice CD276 gene Colorectal Carcinoma Confirmation Dermatitis, Atopic Diabetes Mellitus, Non-Insulin-Dependent Duchenne Efficiency Eisai Facility (object) Immunotherapy for cancer Inflammatory Bowel Diseases Kidney Diseases LB-102 Leqembi Mediation Mounjaro Myers Squibb Neuroscience discipline News [Publication Type] Respiratory syncytial virus Series A alpha 1-antitrypsin direct-to-consumer submission tariffs Antineoplastic Agents Bio CBER CDER Cancer Research Cautionary Warning Complete Flagship Frequency of Responses Johnson and Johnson Malignant neoplasm of stomach Malignant neoplasm of urinary bladder Merck KGaA Muscular Dystrophy Myasthenia Gravis NDA Nance-Horan syndrome North Carolina Parkinson 's disease Pauses Phase 2 Phase 3 trial Recommendation Rheumatoid Arthritis Robert F. Kennedy Jr. Technology Vaccine Safety cardiometabolic cash runway cellular targeting melanoma milestones patient deaths public entity regulatory approval safety profile strategic alternatives 2026 Antipsychotic Agents Astellas Automation Biotherapeutics Blackfoot language Board appointment Boehringer Ingelheim Breakthrough Therapy Cells Clinical Clinical Data Combined Daiichi Drugs, Orphan European (ethnic group) Financial savings HIV prevention Health Hypertensive disease Labels (device) Makary Manufacture Multiple Sclerosis Myeloid Leukemia, Chronic Neurodegenerative Disorders Pharmacotherapy Preventive monitoring Product containing glucagon-like peptide 1 receptor agonist (product) Pulmonary arterial hypertension RNA, Messenger SMPX gene Sankyo Severe (severity modifier) Study models Surgical construction Telemedicine US Vanda Pharmaceuticals biopharma biotech startups diagnostics drug safety healthcare technology immuno-oncology medtech tirzepatide ASCO Amylin Benefit BioMarin Biotech Layoffs Budgets CAR-T therapy CDMO Chronic disease Clearance Drops - Drug Form Elderly (population group) Enhertu Exit IGA Glomerulonephritis Insilico Medicine Japan Leukemia, Myelocytic, Acute MFN Malignant Neoplasms Nation PD-L1 Phase 1b Placebos Prasad Progressive Proteinuria RNA Editing Retirement Revolution Medicines Sectioning technique Series B financing Series B funding Shakeup Surgical aspects Weight maintenance regimen acute alpha 1-Antitrypsin Deficiency biobucks biotech industry cardiometabolic diseases corporate drugmakers early-stage executive order merger obesity drug private equity radioligand therapy subcutaneous Access Adult Antagonist muscle action Asthma BARDA BTK inhibitor Bavarian Nordic Biomechanical compliance Burning Mouth Syndrome Chief Medical Officer Contraceptives, Oral Contract agreement Cystic Fibrosis Disease Outbreaks Dosage Eczema File (record) Gardasil Generalized Genomics Hetlioz Hidradenitis Suppurativa Homo sapiens Identifier Idiopathic Pulmonary Fibrosis Impact food supplement Infant J.P. Morgan Healthcare Conference JPM26 Lenacapavir Licensing Liver diseases Machine Learning Manufacturing Facilities Metastatic castration-resistant prostate cancer PAH PCSK9 inhibitor PREP gene Patient Death Pharmaceutical Services RNA, Small Interfering Response Letter Revenue Scientific Advisory Board Spinal Muscular Atrophy SpringWorks Stock Surge T-cell engager Toxicity aspects VK2735 Veradermics Wegovy pill White House Withdraw (activity) aspects of adverse effects asset bidding war cancer drugs delays digital health financing characteristics jet lag disorder oral SERD partnerships pembrolizumab strategic strategic collaboration upfront payment ATTR-CM Abivax Agencies Aktis Alkermes Anemia Antibiotics Attitude Autistic Disorder Blood - brain barrier anatomy Boehringer CHMP CNPV COPD CagriSema Chronic Spontaneous Urticaria Combined Modality Therapy Commission Congress (U.S. Legislature) Discover ESMO Enliven Therapeutics Exelixis Extension Eylea First line treatment GLP-1 receptor Generic Drugs Genmab HIV HPV vaccine Heather Flick Melanson Illumina Indirect Inflammatory disorder Insmed Intellia LDL Cholesterol Lipoproteins Leukemia Liver Failure, Acute Lundbeck Lupus Vulgaris Measles-Mumps-Rubella Vaccine Multiple Acyl Coenzyme A Dehydrogenase Deficiency Mutation NVIDIA Narcolepsy National Security Neuroinflammation PD-1/VEGF Pancreatic carcinoma Partner in relationship Pediatric brand name Pioneering President brand of dental material Priority Review Psoriasis Review [Publication Type] Roivant Secretary Seizures Sentiment Servier Statistical Significance Supplement Teva Translucent Trump tariffs acquisitions approvals biology (field) biomanufacturing biotech partnerships cash position commercialization daraxonrasib drug review exophthalmos producing substance factor IX giredestrant immunotherapeutics inhibitors launch manufacturability mental health onshoring ovarian neoplasm perioperative personalized therapies pharmaceutical innovation portfolio shipment sonelokimab treatment-resistant depression uniQure 3-Methylglutaconic aciduria type 2 AAVS1 gene AKTS ALV-100 ALV-200 AMT-130 Acquisition (action) Alnylam Alveus Therapeutics Alzheimer 's AnaptysBio Anticoagulants Application procedure BCR-ABL1 BNT327 Bankruptcy Biotech IPOs Blenrep Bourla Buckham CIDRAP CSO Cancer Vaccines Cancer of Neck Cardiovascular system Chronic Kidney Diseases Cobenfy Complete Response Letter Conditional DNA Integration DOGE Decision Deep molecular response Department of Health and Dependovirus Detection Diabetes Mellitus, Insulin-Dependent Drug Delivery Systems Drug Prescriptions Elamipretide Epidermal Growth Factor Receptor Event-Free Survival Evotec SE Failed Forbion Fund Raising GIPR gene GZMH gene Generative AI Gomekli HER2-negative Halda Therapeutics Halozyme Hannah Anderson Head Head of US Heart Diseases Heart failure Hematologic Neoplasms Hong Kong Huntington 's disease IL31RA gene IPOs Immunization In complete remission India Inflammation Insulin Ivonescimab J.MD Jazz LDL-C License Application Licensing Deal LillyDirect Litigation Long-term MAHA Maintenance MariTide-like Maziar Mike Doustdar Menopause Molecular Response MoonLake Mucopolysaccharidosis II Myasthenic Syndromes, Congenital Myelocytic NECTIN4 gene NLRP3 inhibitors Nerve Degeneration Novavax Opdivo Opioids Otsuka PhRMA Phase 1 (qualifier value) Phase 3 clinical trial Platform Post-Traumatic Stress Disorder Prader-Willi Syndrome Presenile dementia Pulmonary Fibrosis R-Series RNA therapeutics Regulation Research Projects Retinal Diseases Rick R. Suarez Risk Rocket Science Score Series B Small Molecule Surveys T-Lymphocyte TIGIT gene TMEM79 gene TYK2 gene Tagrisso Tolebrutinib Triple Negative Breast Neoplasms TrumpRx Twice a day Type B meeting Ulcerative Colitis Ultragenyx Uncertainty Vaccine Integrity Project Ventyx Biosciences Viking Vinay Prasad Virginia manufacturing facility WDR20 gene Wave Life Sciences Wilmington Delaware Window (physical object) Worker analysts asciminib chain disruption dealmaking decision letter deruxtecan developability disbanded drug market engagers erbB-2 Receptor executive appointments financial first focal onset seizures funding grant generative AI human independent review interleukin-6 lawsuit license agreement mRNA Vaccine manager minoxidil monthly patent cliff patent infringement phase advance protocol precision oncology preclinical data protein degrader public health policy recommendation change regulatory submission regulatory uncertainty resignation royalty settlement shareholder single-dose schedule small-cell lung cancer stocks summit tasimelteon trials 2023 ADC ADCs Adolescent (age group) Affordability Agentic AI Akeso Alcon Alexion Alumis Amlitelimab Androgenetic Alopecia Antibody-Drug Antisense Oligonucleotides Ascletis Asymmetric Septal Hypertrophy Atrial Fibrillation Audit Committee Autoimmune thrombocytopenia B-Lymphocytes BEACON-IPF Beyfortus Big Pharma Billion Biologics License Application Bovichtus Brain Neoplasms Breakthrough Therapy Designation BridgeBio CDC CFO CNS disorder CVR California Camzyos Canada Carlyle Cessation of life Chief Legal Officer Childhood Vaccines Chinese Language Chronic Lymphocytic Leukemia Chronic pain Clinical Failure Contraceptives Corporate governance Crohn 's disease DKK1 gene DMD Dianthus Therapeutics Diffuse Large B-Cell Lymphoma Disorder of eye Ditiocarb Diversity Drug Regulations Durham ER-positive Effect Eikon Eli Lilly backing Episodic Europe Event Family Turdidae (organism) FibroGen GLP-1/GIP dual agonist Galapagos Gene Silencing Glycogen storage disease type II Guanosine Monophosphate Healthy Hearings Hepatitis B Hot flushes IRA Immunostimulating conjugate (antigen) Impaired Import InduPro * * Inflation Reduction Act Influenza Injectables Insurance Ipsen Ira (eukaryote) JPM Journavx Jr. K-ras Oncogene Legal Liquid Biopsy Lung diseases Lynkuet M&A activity MYELODYSPLASTIC SYNDROME Macular edema due to diabetes mellitus Malaria Malignant neoplasm of kidney Medical Research activity Merck & Co. Migraine Disorders Misinformation Most-Favored-Nation Muscular Dystrophies, Limb-Girdle Myocarditis Neuropsychiatry New Drug Application New Jersey Nitroglycerin/Sodium Citrate/Ethanol Solution ORR Ogsiveo Oral PD-1xVEGF PDCD1 gene Padcev Paul Hudson Pennsylvania Performance Peter Marks Phase 1b trial Phase 2 clinical trial Phase I Clinical Trials Plant seeds Pliant Pounds Praxis Precision Medicines Precision - temporal Protein Degradation, Metabolic Psilocybin Q2 2025 Q3 2025 Q4 2025 RAS-driven cancers RETINITIS PIGMENTOSA 1 RGX-121 RIPTAC RVMD Rakovina Regenerative Medicine Regulatory Setback Remote Replimune Retinitis Pigmentosa Reversal Rinvoq SanegeneBio Seqirus Series D financing Small Interfering Stealth BioTherapeutics Stock Decline Suspensions TMALIN Talzenna Target Tecentriq Transitory Triglycerides UX111 Urinary tract infection VTX3232 VTX958 Vaccination Vascular Endothelial Growth Factor A ViiV Healthcare Vinay Vital capacity Wall Street Journal Winrevair Workforce Reduction YL201 Yeztugo Zealand Pharma Zolgensma Zymeworks agonists antitrust authorization biotech collaboration biotech sector bounce capital markets chief of chikungunya vaccine chronic clinical endpoints collaboration termination conditions contingent value right court enforcement enzalutamide executive leadership expense generics manufacturing issues measles negotiation nivolumab nrSPMS oncology pipeline oral semaglutide pandemic preparedness pharmaceutical companies pharmaceutical marketing pharmaceutical supply chain pilot program proposal - intent rally real-world data reorganization resubmission revenue growth rumors sNDA skipping strategic review takeover talks targets upadacitinib user fee user fees zanzalintinib ABVX AI drug development AI-designed drug AI-enabled ALS ATR Inhibitor Acelyrin Achondroplasia Acute lymphocytic leukemia Acute onset pain Adjuvant Therapy Advanced phase Age related macular degeneration Agios Albert Alternative Altimmune Americas Angioedemas, Hereditary Antengene Apellis Apolipoprotein E4 Arcus Biosciences Argenx Ataxia Aurora Therapeutics Australia Avidity Biosciences Awareness Beak Bhattacharya Biktarvy Biohaven Biomedical Research Biomedicines Black Populations Blindness BlueRock Therapeutics Blujepa Body mass index procedure Brazil Brinsupri CD19 Antigens CD3 Antigens CDE CE Mark CEOs COMP360 CRDMO Cambridge Capsid Carcinoma breast stage IV Cardiomyopathies Cash Cervical Atlas Charles Chief Chief Financial Officer Chikungunya Fever Chronic multifocal osteomyelitis Clinical Nurse Specialists Clinical Trial Design Clinical Trial Failures Co. Compass Pathways Compound Concentra Biosciences Congenital Construction worker CordenPharma Crackdown CureVac Cystic Fibrosis Transmembrane Conductance Regulator Cytokinetics DNA Datopotamab deruxtecan Datroway Deafness Deal Value Death of child Denali Depletion Dexcom Diabetes Mellitus Disease Progression Disease-Free Survival Does speak Drug Shortage DualityBio Dyslipidemias EBITDA ECCO ESR1 gene Emma Walmsley Employee Endometriosis Enflonsia Evidence Expectations Eylea HD Fabry Disease Familial chylomicronemia syndrome Farxiga Fast Track Florida Freezing Funds Fyodor G-Protein-Coupled Receptors GLP-1/GIP GLP-1s Gastric Inhibitory Polypeptide Genome Geographic Atrophy Germany Glaucoma Glycogen Storage Disease Type IIb HHS layoffs HLD-0915 Hims & Hers Holdings Holly Springs Hormone Therapy Hyperphagia Hypertriglyceridemia Hypertrophic obstructive cardiomyopathy IL33 protein, human Imdelltra Imfinzi Immunome Immunovant Improvement Increase Indication of (contextual qualifier) Indonesian language Infantile Severe Myoclonic Epilepsy Inflation Influenza virus vaccine Ingelheim Injury of liver Inosine Triphosphate Interferes with Ionis Pharmaceuticals Janus kinase Jaypirca Jeffrey Jennifer Doudna Kailera Kinaset Therapeutics Kirin Kisunla Kymera Kyowa Laboratory Laboratory test finding Legos License Liver Liver Failure Logistics Lp(a ) Lupus Erythematosus Lupus Erythematosus, Systemic Lymphoma MC4R protein, human MET-097i MacroGenics MapLight Therapeutics Maria Sainz Marty Marty Makary Medical service Menin Inhibitor Menkes disease Menlo Ventures Mental Depression Mental deterioration Merus Metabolic Midline (qualifier value) Mortality Vital Statistics Myasthenia Gravis, Generalized Myasthenic Syndromes Myopia NAMs NIH NYSE Narcolepsy type 1 Nektar Therapeutics Neurocrine Neurodevelopmental Disorders Neurology speciality Neuromuscular Diseases Neurosecretory Systems New Nkarta Non-Insulin-Dependent Novavax 's Nucala Nxera Pharma Obesity Drug Odyssey Therapeutics OpenAI PARP1 gene Pain management Parity Pathology Patient access Pediatric Disorder Peptides Pharma Industry Pharmaceutical merger Pharmacovigilance Phase 1 trial Phase 2b Phase 3 failure Pipeline Development PreCheck Preclinical Prediction Pressure- physical agent Preventive Health Services Primary Prevention Privacy Project Projections and Predictions Protein-tyrosine kinase inhibitor Proteomics Prothena Psychological inhibition Psychotic Disorders Public Offering Pulse Biosciences Quality R&D pipeline RAP-219 REMS RMAT Rapport Therapeutics Reaction Recursion RegenXBio Regenxbio Regulatory Action Regulatory Affairs Relapsing course RemeGen Repatha Research Personnel Respiratory physiology Restrictions Revenue Decline Rezpeg Richard Pazdur Robotics Rocatinlimab Rosnilimab Rybrevant SPAC Sandoz Saxenda Scholar Rock Science of Chemistry Screening for cancer Secretary Nomination Security - service Senate hearing Series A financing Series D Sibeprenlimab Sofinnova Sotyktu Spikevax SpinCo ' Spinocerebellar Stabilizer - function Stelara Subcutaneous Injections Subgroup A Nepoviruses Supernus Pharmaceuticals Systemic Systemic Scleroderma TNBC TREM2 Takeover Tessera Thermo Fisher Transection (procedure) Trodelvy Trump UPenn Unable to walk (finding) United States National Institutes of Health UnitedHealth Group Uplizna UroGen VAERS VDPHL01 VG-3927 VRBPAC VX-264 Vabysmo Vepdegestrant Verona Viking Therapeutics Viral Vector Vision Winter Park Workers World Health Organization WuXi WuXi AppTec Zenas BioPharma Zorevunersen Zurzuvae adaptation advanced therapies aldosterone synthase inhibitor alixorexton assets asthma drug atezolizumab baxdrostat bemdaneprocel benzamide antipsychotic benzamide class bexotegrast binding affinity biotech acquisition biotech merger bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine board changes branded drugs brensocatib cancer care cancer drug development capabilities childhood vaccine schedule clinical pipeline commercial constraints data integration datasets deal decline departure - ActRelationshipType deramiocel direct-to-consumer sales domestic manufacturing domvanalimab draft guidance drug efficacy drug manufacturing drug shortages exon federal funding federal judge fibroblast growth factor 21 gepotidacin headquarters high-risk iTeos ianalumab ifinatamab inhaled therapy investor language models mCRPC mRNA Vaccines mRNA flu meeting mimetics molecular glue muscle-invasive bladder cancer nPulse nerandomilast nervous system disorder neurological diseases nex-z next-generation obinutuzumab oncology partnership operating profit oral therapies oral treatment ounce oveporexton pacibekitug patent settlement patient death payers payment payments pharmaceutical acquisition pharmaceutical sales pipeline reduction platforms preclinical programs primary endpoint protein degraders psychedelic therapy public trust pumitamig radiopharma rates real-world evidence regulatory compliance regulatory guidance regulatory science remibrutinib research collaboration reshoring roxadustat safety review scalability seed fund shareholders shutdown skepticism small molecule therapeutics specialty medicines spending statutory scheme strategic partnership strategic partnerships strategic restructuring strategic shift succession surge survival talazoparib targeted therapies tariff terminations therapeutic protein tolerability trastuzumab twice-yearly injection type 2 inflammation update upfront vaccine overhaul valproic acid glucuronide valuation value-based care vedotin virtual care women 's health 130-nm albumin-bound paclitaxel 15% 75% 8 AACR AACR25 AAV Vector ABI-5366 ACR gene AERIFY-1 AERIFY-2 AH 001 AI Platform AI biotech AI drug design AI health AI healthcare AI models AI protein design AI-powered AML ANGPTL3 AOC ARD-101 ASC30 ATG-201 ATTRv-PN Aardvark Therapeutics Abeona Abnormality of mitochondrial metabolism Acadia Acceleration Actinium Adaptimmune Administration of prophylactic statin Administrative action Adoption AdvanCell Adverse effects Adverum Biotechnologies Advocacy Age AgomAb Agreement Alagille Syndrome Alameda Headquarters Alzheimer 's psychosis Amazona Ambulatory Care Facilities Amicus Therapeutics Amvuttra Amylin Analog Amyloidosis AnHorn Medicines Analgesics Analgesics, Non-Narcotic Angelini Pharma Antibody Therapy Antimicrobial Resistance Antistreptolysin O Antiviral Agents Anxiety Disorders Apolipoproteins B Appia Bio Apple Watch Apply Arbutus Arcus Arenaria <Aves> Arrowhead Arrowhead Pharmaceuticals Arvinas Ascendis Pharma AsedaSciences Asia, Southeastern Assembly (construction) Atacicept Atopic AutoInjector Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes Automobiles Avadel Pharmaceuticals Availability of AviadoBio Ayrmid Azafaros B-cell depletion BCG-Unresponsive BGM0504 BMS BNC210 BRUIN Bain Capital Bay Area Behavior Beijing Big Beautiful Bill Bill Anderson Bill Cassidy Bio-Rad BioAge BioCapital BioNTech 's BioNeMo Biochemical Pathway Biological Assay Biopharma Sentiment Index Biopharma layoffs Bioscience Biotech Innovation Black Box Warning Bluebird Bio Boston Scientific Breakout Ventures Brepocitinib BrightGene Bronchiectasis Bruton 's tyrosine kinase inhibitor CBO CD19xCD3 CD388 CDK2 protein, human CDK4/6 inhibitor CGM CHF CLL CLN-978 CNP gene COAST COVID COVID-19 Vaccines CRLs CSU CT-996 CTSC gene CUTX-101 Cancer Detection Candidiasis, Chronic Mucocutaneous Capacity Capillary Leak Syndrome Capital Management Capital Partners Caplyta Capricor Therapeutics Carboxyamidotriazole Orotate Cardiff Oncology Cardiology discipline Cardiovascular Risk Cardiovascular event Cartesian Cartography Biosciences Carvykti Cash Crunch Cataplexy Cavazzoni Celltrion Center for Drug Evaluation Cerebral Edema Cerebrovascular accident Chairperson Challenge Chancery Charles River Laboratories Chickenpox Chief Business Officer Chief Commercial Officer Chief Operating Officer Chief Technology Officer Childhood Chimeric Antigen Receptor T-Cell Therapy China-based Chris Klomp Chronic inflammatory disorder Chronic low back pain Chronic neutropenia Chronic sinusitis Chugai Cidara Therapeutics City of Boston Clinical Advisory Board Clinical Decision Support Clinical Oncology Clinical Services Clinical action Closed Cogent Biosciences Columvi Commissioner 's National Priority Voucher Community Company Split Comparative Efficacy Complicated Compounders Conferences Confirmatory Trial Consultation Consumer Safety Continuous glucose monitoring Contract Research Organization Conventional (Clear Cell) Renal Cell Carcinoma Corcept Cosentyx Country Covid vaccine Creative Biolabs Crohn 's & Colitis Congress Cullinan Customer Cutaneous Cylembio DB-OTO DEI DEL-AI DELIVER (veterinary product) DLL3 gene DNA Replication DOJ DOR/ISL Daily Dapiglutide Darzalex Darzalex Faspro Data Analysis Data Safety Daytime Somnolence Deep Apple DeepHealth Deerfield Management Degrader Delaware Delaware Court Dental Plaque Depression Depression, Bipolar Depression, Postpartum Depressive disorder Dermatitis Dermatologic disorders Dermatology field Diabetic Retinopathy Diagnosis Diagnostic Imaging Donald Trump Dordaviprone Dr. Droughts Drug Approval Process Drug Costs Drug Formulation Process Drug withdrawal syndrome Dwarfism Dyne Therapeutics Dystrophin EASI EASI-75 EGFR-mutated ELAVL2 gene EMBARK trial EMMI ENTR-601 ESMO Congress EV-304 Early Diagnosis Ebvallo Economics Ecosystem Edema Electrophysiology (science) Eligibility Determination Elivaldogene autotemcel Elon Employment Termination Endo Engaged to be married Entrada Environment Enzymes Epcoritamab Epigenomics Escherichia coli Evaluation procedure Excessive (qualifier value) Express Scripts Eye FCGRT gene FDA-approved FIBRONEER-ILD FLAURA2 trial FY2025 Fabhalta False Claims Act Familial mitral valve prolapse FcRn Federal Circuit Feedback - system communication Fertility Agents Fertilization in Vitro Fibrodysplasia Ossificans Progressiva Fibromatosis, Aggressive Fibromyalgia Fibrous histiocytoma of tendon sheath Fierce Financial Forecast Revision Flatulence Focal Food Safety Force Fortress Forzinity Foster City Fosun Pharma Fragile X Syndrome France Fraud Friedreich 's ataxia Fujifilm Functional GABA Modulators GE HealthCare GEP-NETs GLP-1/GIP receptor agonist Gaithersburg Gazyva Gemini of Coiled Bodies Gender Gene Expression Gene Mutation Generic Competition Genome Editing Genrix Bio George Tidmarsh Glioblastoma Glycosylated hemoglobin A Goldcrest Goldman Sachs Gonorrhea Govorestat Grail Gram-negative bacteria Groups Gubra Guidelines HBr HELP Committee HER2-mutant HER2-positive carcinoma of breast HIV sales HRS-5346 HYMPAVZI Hallopeau-Siemens Disease Hallucinogens Harbour BioMed Health Care Market Health Care Reform Health agencies HealthBench Healthcare AI Heart Hematologic Tests Hemoglobin A1c measurement Hemophilia A Hengrui Pharma Hengrui Pharmaceuticals Hereditary Diseases Herpes zoster disease High High-Throughput Nucleotide Sequencing Hikma Pharmaceuticals Hillhouse Investment Management Home environment Hong Kong NDA Hospitalization House mice Hua Medicine Hyderabad Hypercholesterolemia Hyperlipidemia Hypersensitivity Hypertrophic Cardiomyopathy Hypoparathyroidism I-DXd IDeate-Lung02 IMNM IMVT-1402 ITM-11 IZERVAY Iambic Therapeutics Ibrance Ideaya Biosciences IgG4-Related Disease Imaavy Imbruvica Immune Immune Medicines Immune System Diseases Immune Tolerance Immune response ImmuneOnco Immunization Schedule Immunogenicity (package insert) Immunoglobulin IgG4 Immunology pipeline Immunoregulation Increased Incretins Incyte Individual Adjustment Induce (action) Infantile Neuroaxonal Dystrophy Infusion procedures Inhibrx Injection of therapeutic agent Innovent Biologics Insitro Inspection (procedure) Intact Intellectual Property Interim Interleukin-17 Interval Intra-Cellular Therapies Intrathecal Route of Drug Administration Invasive Invasive meningococcal disease Inventiva Investor Reaction Io satellite Irish (ethnic group) Isomorphous Ixchiq J&J 's JCR Japanese language Jay Jay Bhattacharya Jemperli Johns Jorna Judge KEYNOTE-B15 KGaA KOL Bulletin KOMET-001 KRP KRP-M223 KRRO-110 KT-621 KYV-101 Kennedy Kerendia King Kisqali Korro Bio Kyorin Kyowa Kirin Kyverna LAVA LBRX LEAP LGBTQ+ LUMRYZ Lab-in-the-Loop Labcorp Lars Fruergaard Jørgensen Late stage Laurie Stelzer Lawyer (occupation) Lazcluze Leadership Transition Lean Mass Lecanemab Letter [Publication Type] Lifting Lightning Step Lila Sciences Lilly Gateway Labs Lilly collaboration Lipid Nanoparticles Litifilimab London Long Intergenic Non-Protein Coding RNA Longevity Lonza Luke Miels Lupus Nephritis Lymphoma, Follicular Lytenava MAGNITUDE trial MASP-3 Inhibitor MBX Biosciences MEK MEMO1 gene MET-233i MHRA MPLT MRGPRX2 gene MRT-6160 MSTAR MYOTONIC DYSTROPHY 1 Mabwell Madrigal Pharmaceuticals Malignant neoplasm of anus Mallinckrodt MariTide Maryland (geographic location) Massachusetts (geographic location) Measures Mechanism Framework MedKey Medical Specialities Medicare Part D Meeting Mehmet Mendra Meningococcal vaccine Mental Recall Mesenchymal Stem Cells Metabolic Syndrome X Mexico Microbicides Microbiome Microglia Microsoft Mike Doustdar Mississippi (geographic location) ModeX Molecular Glue Degrader Monte Rosa Therapeutics Monthly (qualifier value) Motion Sickness Mozafancogene Autotemcel Mucopolysaccharidosis Type IIIA Muscular Dystrophy, Facioscapulohumeral Musk secretion from Musk Deer Mycoses Myeloid cell engager NBD1 NEJM NPM1 Nasal Spray Nasdaq EIKN Nasopharyngeal carcinoma National Priority Voucher Neuphoria Neurofibromatosis 1 New Approach Methods NewAmsterdam Pharma Newleos Nimbus Therapeutics Non-Muscle Invasive Bladder Neoplasms Note (document) Novo Novo Nordisk Foundation Nurix Nuvalent OBBBA ODAC OPKO Health Obefazimod ObesityWeek 2025 Obexelimab Obicetrapib Obstetric Delivery Ocular Toxicity Odyssey Olezarsen OliX Oligonucleotides Omeros Oncolytics Opdualag Open Optogenetics OrbiMed Orexin Receptor Agonist Organization administrative structures Organoids Orphan Drug Designation Oura PANSS PD-1/VEGF bispecific antibody PD-L1xVEGF PHD1/2 inhibitor PLN-101095 PLRX PM359 PP405 PTC518 PYRUKYND Papzimeos Parkinson Disease Partial Parts per million (qualifier value) Paul Offit Penmenvy Pericardial effusion Personalized cancer care Personnel Selection Personnel Turnover Petosemtamab Phage Therapy Pharmaceutical Research Pharmacy facility Phase 1/2 data Phase 2 trials Phase 2a trial Phase I Phase II B Trial Philadelphia Phobia, Social Pipeline Progress Pivot Device Plexiform Pliant Therapeutics Poolbeg Post-Hoc Live Postpartum Precigen Precision immunology Prediabetes syndrome Predictive analytics Pregnant Women Preventive Care Primary Biliary Cholangitis Primary Health Care Primary Hypersomnia Primary amyloidosis Prime Medicine Priovant ProfoundBio Project NextGen Protac Protein Degradation Protein Engineering Protein Tyrosine Kinase Proteins Prussia Public Preparedness Pulmonary Q1 2025 Quality of life Qyuns Therapeutics RAPT RAS RC148 RDEP RECONNECT RGX-111 RNA, Circular RP-A501 RSV RadNet Radiant heater Real-world Evidence Recruitment Recurrent respiratory papillomatosis Reimbursement Relocation of home or business Reparative closure Repertoire Republican Respiration Disorders Response Letters Retinal Vein Occlusion Rett Syndrome Revenue Upgrade Rexulti Rezdiffra Rezpegaldesleukin Rhapsido Rilzabrutinib Rising River Laboratories Robert Langer Rogaine Romvimza Rybelsus Rytelo SABCS SG&A SNCG gene SOPHiA GENETICS SPN-820 STARGLO STAT6 degrader STELLAR-303 Salts Samsung Saphnelo Sarcoidosis Schrödinger Scott Gottlieb Self Confidence Senate Finance Committee Sense of identity (observable entity) Sentynl Therapeutics Septerna Sernova Services Shanghai Sharing (Social Behavior) Shingrix Shockwave Medical Simcere Sionna Site SkySTAR platform Skyhawk Skysona Sleep Social Welfare Social stigmata Sodium Channel Blockers Soleno South Korea Spinal Cord Injuries Spinout Spinraza St. Louis Standard (qualifier) Standard of Care Stem Cell Therapy Steroids Stewardship Stock Crash Stock exchange Structure Therapeutics Subcutaneous Keytruda Substance Use Disorders Sunwave Super Bowl ad Supreme Court Sustained-release Mitomycin C Hydrogel Formulation UGN-102 Suzetrigine Svalbard Switzerland Symbravo Synthetic Biology Syringes T-Cell Receptor TAR 200 TCE TERN-601 TERN-701 TNFSF15 gene TP53 gene TPTE2 gene TSLP gene TSRA-196 TUB-030 TUB-040 Taiho Targeted Protein Degradation Targeted Therapy Tecartus Tecelra Tecvayli Tempus AI Tenaya Therapeutics Tension Terns Terray Therapeutics Texas Thalassemia Therapeutic immunosuppression Thermo Fisher Scientific Thyroid associated opthalmopathies TimeLine Fluoride Releasing Resin Tradipitant TransCon Transaction Translarna Treatment Protocols Treeline Trontinemab Trulicity Trump loyalists Trump vaccine schedule Truqap Tryngolza Tuberculosis Tubulis TuneLab Type 2 U.S.-China UGX-202 US tariffs USPSTF Uncontrolled Union United Kingdom United States Federal Trade Commission United States Health Resources and Services Administration United Therapeutics Universities Unresponsive to Treatment Unsolicited Adverse Event VANQUISH-1 VERVE-102 VESALIUS-CV Vaccine Development Vaccines, Combined Validation Valneva Valo Health Vascular Diseases Vaxart Ventus Therapeutics Vera Therapeutics Verona Pharma Vigil Vimkunya Vir Biotechnology Vyne Vyvgart WVE-006 WVE-007 Wages Wakefulness Walmart Pharmacy Wayrilz Woman Workforce - population group Wugen Xtandi Yale Yescarta Ypsomed ZEVASKYN Zag Bio Zaltenibart Ziftomenib Ziihera Zynlonta abbott access program acute liver injury acute pain treatment addiction aficamten agentic AI alfa algorithm all-stock alpha therapies alpha-Synuclein altretamine/cisplatin/cyclophosphamide protocol amendment amisulpride annual anti-seizure medication anti-tumor activity antiarrhythmic peptide antibody libraries apitegromab appeal at-risk augmented avacincaptad belrestotug benzamide bezuclastinib biopharma executives biopharmaceutical development biopharmaceutical industry biopharmaceutical manufacturing biotech closures biotech downturn biotech partnership biotech startup biotechs black box blood thinner board chair bone health boxed bretisilocin brexpiprazole business career business development buyback cabozantinib calcium glucarate campus cancellation cancer discovery cancer pipeline capitalization carbetocin cardiometabolic health cardiovascular pipeline care activity cell line development cell renal cell carcinoma charge amounts checkpoint inhibitor checkpoint inhibitors cholesterol chronic hand eczema cibotercept claims claseprubart clinical program clinical trial termination commercial strategy contract manufacturing corporate strategy cost-cutting measures coverage - financial contract danuglipron data privacy day deadline deals decentralized denosumab departures deucravacitinib dexamethasone diabetes drug digital pathology digital transformation digital twins direct-to-patient discontinued discount disease prevention disease treatments disruption divestment domestic drug manufacturing domestic partnerships dorzagliatin dostarlimab drug acquisition drug applications drug development halt drug launches drug rejection drug response drug spending durability economic impact election enlicitide envudeucitinib epigenetic reprogramming equity executive appointment executive transition expert fast-track approval federated learning fentanyl crisis fill-finish financial performance firings first-in-class first-in-human first-line first-line therapy gMG gastroesophageal adenocarcinoma gene targets generic pharmaceuticals glucagon glucokinase activator governance growth outlook hair regrowth health data health disparity heart health high-risk groups high-throughput screening human antibody human papillomavirus hydrocortisone import alert improvements incretin drugs inebilizumab injunction investors isononanoyl oxybenzene sulfonate issues itepekimab leadership appointments leadership shakeup leases leukemia lexicon liraglutide liver transaminase lobbying lorigerlimab losses low-grade mRNA cancer mRNA therapies manufacturers mass layoffs mechanism pathway medical AI meloxicam merger agreement mergers mid-stage trial mirdametinib mitapivat mitomycin molecular glue degraders molecular glues multispecific antibodies muscle preservation namilumab navepegritide next-generation biologics non-opioid pain drugs older once-daily once-monthly onvansertib operational oral drug oral obesity drugs oral small molecule oral therapy orexins outcomes patient safety pegcetacoplan pegol pegozafermin pemvidutide personal reasons personalized cancer petrelintide pharma partnerships pharmaceutical competition pharmaceutical litigation pharmaceutical manufacturers pharmaceutical negotiations pharmaceutical partnerships pharmaceutical regulation pipeline cutbacks pipeline focus pipeline pivot pirfenidone placebo-controlled trials platform technology designation plunge portfolio strategy prescription drug costs price cut prime editing probationary workers profit guidance quality management real-time monitoring real-world reality recipients reconciliation recurrence prevention refusal regorafenib regulatory decisions regulatory environment regulatory filing regulatory filings regulatory review regulatory strategy removal technique repeal research funding reshuffle resilience retatrutide review extension risk mitigation risk-benefit analysis rizatriptan second-line treatment seconds sertraline sevabertinib shionogi solbinsiran spindle orientation checkpoint startup startups stock crash stock drop stop work strategic brands strategic realignment subcutaneous formulation sustainability synergies taletrectinib tariff exemption tenosynovial thimerosal third quarter 2025 threat tourmaline travel treatment failure treprostinil palmitil inhalation powder trial design triple agonist troriluzole tumor-activated tumor-selective antigens ustekinumab vaccine access vaccine deaths vaccine schedule vasomotor symptom vatiquinone velinotamig venetoclax vera vormatrigine warning letters webinar weight-loss pill wet age-related macular degeneration winners workforce reduction xRNA zimberelimab zimislecel (3beta * * European Life Sciences Coalition * * Global Expansion * * * * Riad Mishlawi * * * * Vivek Ramaswamy * * * * atopic diseases * * * * functional cell 10 mg 15B 1964 200 2024 2026-2035 24-Hour Data 3-(2-methoxyphenyl)-5-methoxy-1,3,4-oxadiazol-2(3H)-one 30% 340B 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-3-indacene 4D Molecular Therapeutics ' 50–59 55% 5alpha)-isomer 6-amino-1-hydroxyhexane-1,1-diphosphonate 7.5 mg 8(a 90% 95% AAAAI AACR 2026 AACR-NCI-EORTC AAER AARD gene AAV antibodies AAV-AIPL4 AAV-based gene therapy AAVB-081 AAVantgarde AAVrh74 AAVrh74 vector AB-2100 AB001 ABPI ABS-0871 ABS-1230 ABTECT-1 ABTECT-2 ACHIEVE-1 ACI-7104.056 ACP-101 ACR-2316 ACTN4 wt Allele ACUA AChR-Ab AD109 ADA25 ADAMTS-5 ADAPT-PD study ADARx ADEL ADEPT-2 trial ADMET AFFINITY DUCHENNE trial AFFIRM-1 AFFIRM-1 phase 3 trial AHA AI Assist AI Factories AI Proteins AI Stethoscope AI agents AI antibiotic discovery AI biomarker AI guardrails AI healthtech IPOs AI humanoid robots AI lab AI oncology imaging AI platform AI safety AI skills AI supercomputer AI therapeutics AI tool AI ultrasound AI workflows AI-Based Protein Design AI-based AI-based drug discovery AI-designed AI-designed molecules AI-discovered drugs AI-engineered antibody AI-generated AI-guided AI-native platform AI-powered diagnostics AI-powered drug discovery AI-powered healthcare AI/ML-enabled product AIM-MASH AIR-001 AK006 AKAP9 protein AKAP9 protein, human AKY-1189 AL ALK Inhibitor ALK gene ALKOVE-1 trial ALPHA3 trial ALT-positive ALTO-203 ALZ-801 AMD AMG AMONDYS AMPA receptor modulator AMPA-PAM AMT-191 AMX0035 ANDA ANX005 AP01 AP02 AP3 APIs APJ AQUILA study AR navigation ARC-EX System ARCT-032 ARG-007 ARIA ARIA risk ARIA-E ARID1A mutation ARO-ALK7 ARO-C3 ARO-INHBE ARO-SNCA ARPA-H grant ARROS-1 trial ARTBIO ARTV ASC41 ASCEND trial ASCENT ASCO GI 2026 ASCO preview ASCO-GU ASCO25 ASCVD ASGCT ASPR ASTX029 ATG-022 ATG-125 ATG-207 ATI ATMP regulation China ATNM-400 ATR ATR/mTOR Inhibitors ATSN-101 ATSN-201 ATTAIN-2 ATX01 AURN001 AVB-114 AVD-104 AWS HealthLake AXS-14 AZD0120 AZD0780 Abata AbbVie CEO Abbas Kazimi Abbreviated New Drug Application Abcam Abe Bassan Abecma AbelZeta Abeona 's Abetalipoproteinemia Absci Academia (organization) Academy of Pediatrics Accelerate Diagnostics Accord BioPharma Accurate (qualifier) Accuray Achieve Life Sciences Acne Vulgaris Acoramidis Acrivon Acromegaly Actimab-A Actinium Pharmaceuticals Actio Actithera Active Activin E :* * Actuate AcuCort Acute leukemia Adagene Adangme language Adaptive Biotechnologies Adcetris Addictive Behavior Adenosine deaminase deficiency Adenovirus Infections Adherence (attribute) Adherence To Medication Regime Aditum Adjunctive Orthodontic Procedure Adjuvant Melanoma Admilparant Adolescence AdvaMed Diabetes Sector Advanced Imaging Suite Advanced Manufacturing Technology Advanced Melanoma Advanced Therapy Medicinal Products Adverse reaction to drug Advertising (activity) Advisory Board Advisory Panel Advita Ortho Aerska Afami-cel Afimetoran Africa Aggressive Aggressive Periodontitis Agilent Aging Agios Pharmaceuticals Agitation Ahmed ElNawawi AiTEM AimedBio Airna Ajax Health Akeega Akeso 's Alarm device Albert Bourla Alberto Lopez Toledo Alchemab Alcohol Use Disorder Alcohol abuse Alcohol or Other Drugs use Aldeyra Aldose Reductase Inhibitor Alector Alejandro Weinstein Alexander Disease Algen Biotechnologies AlgoTx Alkeus Allakos Allergy to peanuts Allison Candido Allo-Glue platform Allogene Allogeneic Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019 Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010 Allogeneic Human Stem Cell-derived Pancreatic Islet Cells VX-880 Allogeneic bone graft Alloimmune thrombocytopenia Alluminox Alma AlphaDirect technology AlphaFold AlphaMedix Alphabet Altanine Alteogen Altman Altuviiio Alva Therapeutics Alveltamig Alyftrek Alzheimer Alzheimer 's disease psychosis Alzheimer 's treatment Amarin Pharma Amazon Health Amazon Web Services Ambros Therapeutics Ambrx American Depositary Receipts American Epilepsy Society 2025 AmericasMedicines.com Amezosvatein Amgen 's Amgen Uplizna Amgen settlement Amolyt Amphastar Amplia Amplify trial Amsterdam facility Amtagvi Amylin Candidate Amyloid beta-Peptides Amyloid-targeting therapy Amylyx AnTenGager Anabolism Analog Anaphylm Anatol Andembry Andreas Goutopoulos Andreas Wallnöfer Andreessen Horowitz Andrew Grethlein Andrew O Andrew Witty Andy Thomas Anemia, Sickle Cell Ang2 Angela Breton Angelini Industries Animal Health Animal Testing Animal Welfare Animal mane Anktiva Ankylosing spondylitis Ankyra Therapeutics Ann Arbor Anne Anne Wojcicki Annexon Anniko Anomaly Ventures Ansa Ansa Biotechnologies Anselamimab Ant Afu Ant Group Antares Anthos Anthropological Culture Anti-BTN3A Agonistic Monoclonal Antibody ICT01 Anti-CD19 Monoclonal Antibody Anti-CD36 mAb Anti-CD52 Monoclonal Antibody ALLO-647 Anti-DR5 Agonistic Monoclonal Antibody INBRX-109 Anti-Inflammatory Agents Anti-Kickback Statute ( Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antibiotic Resistance Antibiotic Resistance, Microbial Antibiotic therapy Antibody Therapeutics Anything Anzupgo Apheris ADMET Network Apis (invertebrate) Apnimed Apollo robot Appeals court decision Apple Health Applied Pharma Apptronik Apretude Aquestive Therapeutics Aqvesme Araris Arbitrating Arbuckle Arc Bio Arcellx Arch Biopartners Arch of foot Architecture Arcturus Arcturus Therapeutics ' Arena BioWorks Areteia Arexvy Arginine Vasopressin-Neurophysin II Preproprotein Argo Biopharma ArsenalBio Arteriosclerosis Arthritis Arthrosi Artificial (qualifier value) Artificial cardiac pacemaker Artiva Biotherapeutics Asarina Ascenta Capital Asia-Pacific Asian Americans Asian Indian Aspect - Kind of quantity Astellas Pharma Astex AstraZeneca 's Astria Astrin Biosciences AstroRx ® Atai Life Sciences Atara Atara 's Atara Biotherapeutics Ataxia Telangiectasia Ataxia, Spinocerebellar Athetoid cerebral palsy Athlone facility Atropos Health Atsena Attention Attenuated by (contextual qualifier) Attruby Atypical Aubrey C. Galloway Augmented Reality Autism Spectrum Quotient Autoantibodies Autoimmune Alliance Autoimmune Chronic Hepatitis Autoimmune hemolytic anemia Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F Autonomous Research Avacta Avadel Avalyn Avastin Avenzo Average Aves Avicanna Avidity Avobis Bio Awards Axial Axpaxli Axplora Axsome Axsome Therapeutics' Ayvakit Azure A³ Strategy B Cell Llama B cell immunomodulator program B-Cell Lymphomas B-Well trials B-cell Select ™ technology B7H3/PTK7 bispecific TOP1 BAFF‑R BAG3-associated BATNA BBB BBI-355 BBI-825 BCG Vaccine BCL6 gene BCMAxCD19 BCR BDTX-4933 BHB-1893 BHV-7000 BI BIC/LEN BII BIOSECURE BL-B01D1 - 303 BLA BMB-101 BMB-105 BMS-986177 BMS-986322 BNT211 BPL BPSI BRCA BRENTUXIMAB BROADWAY BROADWAY trial BTKi BTN3A BW-20829 BX211 Baby KJ Bacterial Infections Baker Bambusa Therapeutics Bangalore plant Barakat syndrome Barinthus Barrow Neurological Institute Barzolvolimab Base Editing Basketball game Bassas da India Batoclimab Bausch Health Beam Therapeutics Beat Becker Hewes Becker Muscular Dystrophy Belén Belén Garijo Bench International Benedikt von Braunmuehl Bepirovirsen Beqvez BerGenBio merger Berkeley BetterHelp Bettis Bharat BiLockCatcher Bias (Epidemiology) Bicara Therapeutics Bicillin L-A Bicycle Bicycle Health Big Data Big Pharma investors Biliary Tract Cancer Bilirubin Bill Adams Billion Collaboration Bimzelx Binding action Bintrafusp alfa Bio + Health Bio-Informatics Bio-Techne Bio-Thera BioArctic BioAtla BioCity BioClec BioCryst BioSpace BioVU BioVie BioXcel Therapeutics Biochemistry Biocodex Biocon Biologics Bioconjugation Platform Biocytogen Bioeconomy Bioepis Biogen CEO Biohaven troriluzole BiomX Biomanufacturing Strategy Biomedicine Biopharm Biopharma regulatory issues Biopharma trade war Biopharmaceuticals Biosafety Biotech Competition Biotech Fundraising Biotech Layoff Tracker Biotech pipeline shift Biotechnology Advantage Bipartisan Support Bipolar I disorder Bitopertin Bivamelagon Blackstone Blackstone Life Sciences Blackwell Ultra GPU Blepharitis Blood Blood Coagulation Disorders Blood Pressure Blueprint Medicines Board Resignation Board change Boards (medical device) Bobby Hunter Body Composition Boltz-1 Boltz-2 Bone Density Bone Diseases Boost Boston Pharmaceuticals Boston event Boundless Brain Brain Delivery Module Brain Research Brain-Computer Interfaces Brain-Penetrant Drug BrainSpace BrainTransporter platform Brainomix Brainomix 360 Brainshuttle Braveheart Bio Brendan Doran Brexit impact Breye Therapeutics ' Brian Armstrong Brian Cherry Brian Thomas BridGene Bright Minds Biosciences Brilaroxazine Bristol-Myers Squibb BroADen Phase 1b trial Broad Institute Bruce D. Forrest Bruin-CLL-314 Bruker Corporation Bullous pemphigoid Burden BurstDR Buyout Bysanti C-CAR031 C-reactive protein C-suite changes C1QA gene C3 G C3 complement inhibitor C3 glomerulopathy C5 inhibitor CAB CABA-201 CADe/CADx CALD CALR gene CAMP4 CAN-2409 CAN10 CAP-002 CAPItello-280 CAPS-5 CAR T-cell CAR-iNKT cells CARsgen Therapeutics CB1 inhibitor CBI-1214 CD CD20 Antigens CD20-directed therapy CD3 T cell CD38 Antigen CD4 + T-cell CD47 Antigen CDC vaccine recommendation CDC7 protein, human CDH17 protein, human CDH6 gene CDK inhibitors CDK2/4 degrader CDMO/CRO CDMOs CE-IVD CELMoD CEO Mike CEO replacement CEO resignation CEPI CETP CHEK1 protein, human CHORD trial CHRS CHW Access Act CIAS CIDP CAPTIVATE trial CIHR CLD-423 CLL-313 CLL-314 CLUS CMO appointment CMS CMS Interoperability Framework CMT-SORD CNS activity CNS-penetrant COM503 COM701 COMPOSE trial CORALreef CORALreef AddOn CORALreef Lipids CORALreef trial CPI-refractory tumors CPOX gene CR-001 CRB-701 CREM gene CRISPR CRISPR therapies CRISPR therapy CRL CRO CROI CROs CRPS-1 CSNK1E gene CT-132 CT-388 CTAD CTMS CTPS1 inhibitor CTX310 CUE-501 CX-2051 CXCR4 gene CYPRESS study Cabaletta Cabaletta Bio Cabometyx Calcified (qualifier) Caldera Therapeutics Calico Califf California residents Calley Means Calquence Calypso study Cambridge Massachusetts Cambridge research labs Camilla Harder Hartvig Camurus Canadian Cancer Society Canal Row Advisors Cancer Drug Sales Cancer Prevention Cancer Research Institute Cancer Risk Candel Candel Therapeutics Cannes Cantargia Cantor Capability Capital Expenditures Capital Markets Capricor Caps Capsida Biotherapeutics Captain T Cell Carcinoma in Situ CardIQ Cardamyst Cardiac ablation Cardiac monitoring Cardiff University CardioMEMS Hero Cardiospermum grandiflorum Cardiothoracic surgery specialty Cardiovascular Agents Carduelis cannabina Caremark Rx Carl Dugart Carl June Carlo Incerti Carlos Quezada-Ruiz Carole Ho Caroline Dorsa Cartography Case (situation) Casgevy CatalYm Catalent Catalent Indiana Celcuity Celea Therapeutics Celiac Disease Cell Culture Techniques Cell Differentiation process Cell Engineering Cell Shuttle Cell-free protein CellCentric CellOPTIQ Cellares Celldex Cellular Origins Center for Biologics Evaluation and Research Center for Drug Evaluation and Research Centers for Medicare & Medicaid Services Centers for Medicare and Medicaid Services Central Nervous System Agents Ceperognastat Cerberus Ventures Cerebral Adrenoleukodystrophy Cerebrotendinous Cereno Scientific Chad Chance Act Changchun GeneScience Pharmaceutical Change, Organizational Charcot-Marie-Tooth Disease Charles Fuchs Charles Ryan Charles Weissmann ChatGPT Health Chaudhuri Chechen language Checkpoint Therapeutics Chemify Chemputation Cheryl Lubbert Chickenpox Vaccine Chief AI Officer Chief Clinical Officer Chief Marketing Officer Chief Product Officer Chief Quality Officer Chief Revenue Officer Chief Strategy Officer Children Program Chimera organism Chimerix Chimerix acquisition China 's China approval China legal issues resolution China pharma China-sourced asset Chinese Neurosurgical Journal Chinese biotech Chinese study Cholestasis-edema syndrome, Norwegian type Cholesterol Drug Cholinergic Receptors Chondrosarcoma Chordoma Chorea Chorionic Villi Sampling Chris Barry Chris Boerner Chris Shibutani Christophe Weber Christopher Martin Christopher Viehbacher Chromatography Chronic Care Management Chronic Condition Chronic Inducible Urticaria Chronic Inflammatory Demyelinating Chronic Obstructive Airway Disease Chronic granulomatous disease Chronic heart failure Chronic lung disease Cigna Cigna 's Ciliary Neurotrophic Factor CinCor Pharma Circuit Cirrus Citation Cityblock Health Civil Rights Act Clarametyx Biosciences Claros facility Class II Medical Device Classical galactosemia Claude Allary Claudin 18.2 ADC Claudin-18 Isoform A2 ClearStrand-ASD Clearmind Medicine CliCr Click Therapeutics ClinVar Clinical Decision-Making Clinical Deployment Clinical Equipoise Clinical Evaluations Clinical Relevance Clinical Setback Clinical Trial Suspension Clinical Trial Termination Clinical pharmacology discipline Clinician CloakLink linker technology Cloning Vectors Closed Loop Medicine Clyde Biosciences Clywedog Therapeutics Co-Diagnostics Co-Dx PCR platform Coartem Cognition Therapeutics Cognitive function: planning Coherus Oncology Coinbase Coleman Colonic Polyps Combined immunodeficiency disease Comirnaty Commercial Managed Care - Pharmacy Benefit Manager Commercial Officer Commission approval Commissioner Committee Communicable Diseases Communication Communications Media Community Health Workers Comorbidity Comparative Genomics Comparison Compass Compassionate Use Compensation Committee Complement Inactivating Agents Complete Response Letters Complex Complex Regional Pain Syndromes Comprehensive Compugen Computational Biology Computer Security Concentra Condition Congenital Cytomegalovirus Infection Congenital deafness Congenital disorder of glycosylation type 1A Congress reauthorization Connect (action) Connecticut biotech Constellation platform Constitutional Challenges Consumer Continuance of life Continuous Delivery Continuous Glucose Monitoring System Contraceptive Implant Contraceptive methods Contrave Corbus Pharmaceuticals Corcept Therapeutics' Core CorestemChemon Corneal epithelial defect Corporate Update Correspondence as Topic Corsera Health Corstasis Corvus Corvus Pharmaceuticals Corxel Pharmaceuticals Cosette Pharmaceuticals Cost Control Cost Savings Cost savings programs Court of Chancery Covalent Interaction Coya Therapeutics Craig Crews Cranial Navigation platform Craving for alcohol Creatine Kinase Crescent Biopharma Creyon Criminal Justice Crinetics Crisis Cristal Therapeutics Cryptigen CryptoMap platform Crystalys Therapeutics Ctexli Cu-Zn Superoxide Dismutase Cues Curapath CureVac acquisition Curevo Vaccine Curon Biopharmaceutical Cushing 's syndrome Cutaneous sarcoidosis Cyclin-Dependent Kinases Cylinder Health Cynata Cyprium Therapeutics Cyprumed Cytek Biosciences Cytology diagnosis CytomX Cytomegalovirus Infections DARPA-funded initiative * * DAWN DAZALS trial DCT gene DDX11-AS1 gene DECODE DFO DIA AI Consortium DILI DLBCL-1 DLL3 DLL3-targeting therapy DMR-001 DNA Methylation DNA Repair DNA Sequence DNA Sequence Rearrangement DNA-damage response DNTH DNTH212 DOGE 's DPP1 inhibitor DREAMM DREAMM-8 DSO DT-101 DT-9081 DTC DTC Campaign DURAVYU DURECT DURGA-1 DXCM DYNAMIKA DYNE-251 Dana-Farber Danish pharma Danyelza Dark Blue Therapeutics Dark color Darovasertib DartsBio Darwazah Dasynoc Data Analytics Data Fidelity Data Integrity Data Lakes Data Management Data Quality Data Release Data Science Data-Driven AI Databricks David Guyer David Meek David Schenkein Day 2 Daymark Health De Novo DePuy Synthes Deal Flow Deal Structure Decatur Illinois December 2025 Deciphera acquisition Deep Brain Stimulation Deep Learning DeepSearch DeepSeq Deerfield Deficiency Degenerative polyarthritis Degrader-Antibody Conjugates Degree or extent Del-zota Demand (clinical) Dementia Research Institute Demis Denifanstat Denmark Dennis Dean Dental Solutions Department of Justice Departure - action Depemokimab Deraphan Dermatographic urticaria Dermatomyositis Derrick C. Li ; Chief Business Officer Desiree Cain Deutsche Bank Develop Developing Dexpramipexole Diabetes Therapy Diabetic Nephropathy Diabetic monitoring - injection sites Diagnostic Accuracy Diamond Therapeutics Diastasis Diet, High-Protein Difficult-to-Express Proteins Diffuse Glioma Digital Technology Digital Trial Digital digestive health Digital innovation Digital therapeutics Dilution technique Dimitri Azar Diorasis Diphosphonates Diphtheria-Tetanus-Pertussis Vaccine Direct-to-Consumer Advertising Directed share Disability Disasters Disc Medicine Dispatch Bio Disputes Dominance Donna Haire Dopamine D2 Receptor Dorsal Dose-Limiting Doustdar DoveTree Medicines Dr. Sara Brenner Draig Dren Bio Drug Compounding Drug Design Drug Development Tool Drug Kinetics Drug Negotiation Program Drug Overdose Drug Pricing Program Drug Repositioning Drug licensing Drug packaging industry Dry AMD Dry Eye Syndromes Duato Dupixent-in-a-pill Duvakitug Dynamic Shared Ownership Dynavax E. coli disease E100 survey EB613 ECLIPSE program EDIT-401 EDNRA gene ELEVATE-44 ELSC ELT ELV001 ELVN EMBARK EMBER-3 trial EMPEROR EMPEROR Phase III trial ENCELTO ENPP1 gene ENT1 ENaBL Platform EO-1022 EO-3021 EOC EOS-215 EOS-984 EP'949 EP4 Antagonist ONO-4578 EP4 antagonist EP4 receptor antagonist EPCORE EPI-321 EPKINLY EPRAD ER-100 ER-Positive HER2-Negative Breast Cancer ES-SCLC ESC25 ESK-001 ESMO IO ESSDAI ETA EU AI Act health EU Approval EUA EVO301 EVO756 EVOKE trial EVOQ EXCALIBER-RRMM EXHALE-4 EY EZH2 protein, human Earendil Labs Early Intervention (Education) East Asian American East Asian Americans East Windsor facility Ecnoglutide Economic Conditions Economic Growth Economic Investment Committee Edap Edenbridge Edgewise Therapeutics Edison Oncology Editas Medicine Efruxifermin Eight Electroencephalography Electromechanical dissociation Electronic Electronic Health Records Electroporation Eledon Elektrofi ElevAAte Elevara Medicines Eli Lilly ; Novo Nordisk Eli Lilly acquisition Eli Lilly competition Elinzanetant Eliquis Elix Elizabeth Montgomery Ella Platform Eloralintide Elraglusib Elsa Emblaveo Emergency Situation Emergency Use Authorization Emergency department patient visit Emergent BioSolutions Emi-Le Emirati Genome Program Empaveli Employer Empower Pharmacy Empowered Empress Emrelis Enanta Enbrel Enbumyst Encapsulated (qualifier value) Encephalitis Encephalitis, St. Louis Encephalopathies Encryption End Point Endogenous Eneboparatide England Enhance (action) Enki generative AI Enlaza Enrollment Entera Bio Enterprise Entity Enveda Environmental pool Enzeevu Enzyme Replacement Therapy Epicrispr Epidemic Epidemic Preparedness Innovations Epigenic Epiminder Epitopea Equillium Equipment and supply inventories Erasca Erelzi Erica Palsis Erica Taylor Erik Atkisson Erythrocytes Erythropoietic Protoporphyria Escalation EsoBiotec Esophageal Neoplasms Esperion Essential Tremor Estimated Estrogen receptor positive Ethics Ethics Committees Etiome Eua (gastropod) Eucalyptus Eukaryotic Cells Europe market European Group for Blood and Marrow Transplantation risk score (assessment scale) European Medicines Agency Evaluate report Evan Rachlin Evernorth Evfraxy Evommune Evopoint Biosciences Evrysdi Ex-FDA ExPEC9V Exact brand biomedical or dental material Exciva Exdensur Executive Board Executive Board Changes Executive Leadership Team Executive Order 14273 Exercise Exit activity Exons Expanding Expedition Medicines Experience Experimental drug Expert Systems Expiration Exposome Extencilline External Director External Ventricular Drain Eye Drops Eye safety EyePoint EyePoint Pharmaceuticals Eyebrow structure Eyelash Eylea biosimilar FAERS FALKON FDA-approved therapies FDA/EMA regulatory pathways FINEARTS-HF FL-501 FOG-001 FORTITUDE-101 FORTITUDE-102 FOXD3 gene FSP FUROSCIX FXR314 FXS6837 Facilities Association Facioscapulohumeral Factor XI Factor XI antibody Factor XIa inhibitor Factory Fair Language Proficiency Family Fringillidae (organism) Family suidae Fanconi Anemia Farapulse Faslodex Favored Favored Nation Fear (Mental Process) Febrile Convulsions Federal Appeals Court Federal reduction-in-force statute Federated AI Feeling content Fees Fellows Ferring Ferring Pharmaceuticals Fetal and neonatal alloimmune thrombocytopenia Fetus FibroGen 's Fibromatosis Fibrosis Fibrosis, Liver Fill/finish Financial Stress Financial Times Findable Fine - adjective First-in-Human Clinical Trial First-in-Human Study Fiscal 2026 Flare platform Flatiron Health Flexible Flow Flow Cytometry FlowMod Flu A/B FluBlok FluidCrystal technology FluoGuide Fluzone FogPharma Food Allergy Food Policy For which was done Forced Vital Capacity Formation Bio Formula - diet Fortrea Foundations Fractyl Health Francis Francis Braun Francis Wilson Frankfurt plant closure Frazier Life Sciences Free Mind ' Campaign Free Nurse Program ' Fresenius Fujifilm Biotechnologies Functional improvement Fund I Fund III Futility Future FutureTech II G12C inhibitors G12D inhibitor GABA A GALA peptide GB-0895 GBS GCG GCG/GLP-1 agonist GDF8 protein, human GDUFA IV GE8820 GEMINI trial GEN1107 GH Research GH001 GI care GI oncology GLA GLM101 GLP-1 medications GLP-1 pill GLP-1/GIP agonist GLP-1/GIP co-agonist GLP-1/GIP therapies GLP-1/GLP-2 GLP-1/glucagon GLP-1RA GLPG5101 GM-2505 GMMA platform GMP violations GO29781 GPC3 protein, human GPCR pipeline GPCRs GPR182 gene GRADUAL-3 GRAS Reform GRT-001 GS-0321 GS-098 GS-1720 GS-4182 GSBR-1290 GSK 's GUB014295 GUBamy GUTC GXO GalNAc Galafold Galapagos layoffs Galatea Bio Galaxies Galderma Galecto Galleri Galleri test Galux Gamma/Delta T-Lymphocyte Gan & Lee Pharmaceuticals Gardasil sales Garetosmab Garijo Gastrointestinal Neoplasms Gastrointestinal Stromal Tumors Gastroparesis Gate Bioscience Gateway Labs Gaucher Disease Gavi Vaccine Gdańsk Gefion AI Supercomputer Gefurulimab GemPharmatech GenEvolutioN GenSci Gene Expression Profiling Gene Writing Gene-Edited Genelux Corporation General Data Protection Regulation General Meeting Generalized pustular psoriasis Generate Generation Park Generations Generative Phosphoproteomics Genes Genetic Biomarkers Genetic Leap Genetic Medicine Genetic Profile Genetic screening method Genetic testing for cancer risk Genetix Biotherapeutics Genevant Geno J. Germano Genomenon Genomic Orientation Genotype Genus Aviceda Genus Malus Genus: Coronavirus GeoVax Geoff Hamilton ; Chief Financial Officer Geographic Intersection Geographic Locations German language Geron Geron Corporation Gestures Giant Cell Arteritis Giant Cell Tumors Gilgamesh Glenmark Glenn Coleman Glickman Glioma Global Biobank Global Health Global Restructuring Global commercial operations Globalization Glucagon-Like Peptide 2 GlycoEra Glycomine Good Machine Learning Practice Google Gordon Gossamer Bio Gossypium Gout Gout Suppressants Government Shutdown Grabody-B Grace Niu GramEye Grand Prix Graphene Gray Delany Great Healthcare Plan Gregory Verdine Grin Gross (qualifier value) Gross margin Growth Differentiation Factor 15 Grünenthal Guardant Health Gubra Ventures Guidance 2024 Guillain-Barré syndrome Gumokimab Gurunathan Gut-Brain Health GxP Gyre stock H. Martin Seidel , H2H trial H5 avian influenza H5 bird flu HDV RNA HER2- HER2-low HER2-positive HER2-positive metastatic breast cancer HER2-targeted therapy HER2-targeting antibody drug conjugate HER2-ultralow HER2CLIMB-05 HER3 HERCULES trial HFmrEF HFpEF HHS Overhaul HIF-2a HIV franchise HKEX HOOKIPA HOPE-2 trial HOPE-3 trial HR+ HRS-9821 HS-001 HS-20094 HS-20110 HSE HSV-1 viral vector HTGS26 HTS HU6 Hahn Hair Analysis Hairy Cell Leukemia Haleon demerger Halle Halo brace Halozyme Therapeutics Hamed Khalili Hand Strength Hansoh Pharmaceutical Hansoh Pharmaceuticals Harbour Mice technology Harbour Mice ® technology Harmony Biosciences Harout Harris Lazarre Harvard Research Harvard University Hassabis Hatteras Hatteras Opportunity Fund I Hatteras Venture Fund VII Haya Hazard Ratio HeFH Head of Growth Head of Non-Clinical Development Health & Wellness Health Care Sector Health Care Systems Health Data Innovations Health Data Research Service Health Data Research UK Health Equity Health Improvement Health Information Systems Health Personnel Health Services Research Health Services, National Health Workforce Health conditions:-:Point in time:^Patient:- HealthCare Royalty Healthy America Hearing Heather Knight Helicon peptide platform Helicore Helix (Snails) Hematology (discipline) Hemgenix Hemlibra Hemophagocytic Hemophilia B Hengrui Hepatitis D Infection Hepatitis, Alcoholic Hereditary Hereditary Diffuse Leukoencephalopathy with Spheroids Hereditary pancreatitis Hernexeos Herpes NOS Herpes Simplex Infections Hers Heterogeneity Heterotopic Ossification Hidradenitis High Drop-Out Rate High dose High-Frequency Microsatellite Instability Highest Hikal HilleVax Hillhouse Capital Hiroyuki Sonoda HistoSonics exit Histone deacetylase inhibitor Histopathological aspects Hodgkin Disease Hoist device Holistic epilepsy management Home Use Honeymoon Effect Hong Hong Kong IPO Hongjiang Miao Hookipa Pharma Hormone replacement therapy Hospital admission Hospital specialist House Appropriations Committee Houston Human Factors Human Glandular Kallikrein 2 Human Services Secretary Humanitarian Exemptions Humira Humira patent expiration Hungary Huntington Disease Hyaluronic Acid anchoring platform Hypercholesterolemia, Familial Hypercon Hyperinsulinism Hyperphosphatemia (disorder) Hypertrophic cardiomyopathy without obstruction Hypocupremia Hypoglycemia Hypoimmune Technology Hypothalamic obesity Hypothalamic structure Høiland IBC IBI343 IBI363 IBTROZI ICER ICU ICU bedside procedures ICU nursing shortages IDE034 IDEAYA Biosciences IDO1 IDS gene IDWeek IDeate-Lung01 IGF-1R Antisense Oligodeoxynucleotide-treated Autologous Glioma Cells IGV-001 IGF1R gene IGNYTE trial IGYNTE II IL-17A monoclonal antibody IL-2 pathway IL-23 receptor antagonist IL-31 receptor alpha IL13 gene IL1RAP antibodies IL1RAP protein, human IMC002 IMM2510/AXN-2510 IMNN-101 IMPACT trial IMVT IMforte trial IMvigor011 INAVO120 INBRAIN INBRX-101 IND-enabling studies INF904 INHBE INHBE gene INLIGHT trial INZ-701 IPG IPS test IQVIA IRAK3 gene IRAK4 gene ISAC ISB ISM4808 ITK gene Iambic Icebergs Ichnos Glenmark Idorsia IgG4-RD IgG4-related disease IgM antibodies Igalmi IkT-001Pro Illinois (geographic location) Illumina Ventures ImCheck Therapeutics Image Analysis Group Imagio Imaging System Imcivree Imlunestrant Immune Activation ImmunityBio ImmunoPrecise Antibodies Immunoassay method Immunocompromised Host Immunofoco Immunoglobulin M Immunologic Adjuvants Immunopharma Impacts, Environmental Impaired cognition Improved Improving (qualifier value) Imsidolimab Imunon Imvax In Vitro [Publication Type] Inavolisib Incentives Incheon Inclusion India 's Indiana Indianapolis Indication restriction Individualized Indivior Infant, Newborn Inference Infinity Smart platform InflaRx Ingram Inhaler Inhibikase Inhibikase Therapeutics Initiative Inluriyo InnoCare Innovative Health Initiative Innovative Medicine Innovent Innoviva Inobrodib Inozyme Inspira Technologies Instill - dosing instruction imperative Instrument - device Insurance Premiums Intas Intellidrop Intelligence Intent Biologics Intercept Pharmaceuticals Interdisciplinary Studies Interius BioTherapeutics Interleukin-13 Interleukin-2 Interleukin-23 Subunit p19 International International Aspects International Drug Prices Interoperability Interoperable Interventional Urology Interventional procedure Interventional radiology Intervertebral Disc Degeneration Interview IntraBio IntraBio Ltd. Intranasal approach Intravascular Invest Europe Investigational New Drugs Invivyd Ionis Iovance Biotherapeutics Iptacopan Ireland Irish healthcare Ironwood IsoDDE Isomorphic Labs Israeli (population group) Itovebi Itvisma Ivory Ixchiq vaccine Ixo-vec Izervay JAK/SYK inhibitor JAK1/TYK2 inhibitor JAM JAMA study JC Virus JCV JN.1-lineage JNJ JNJ-2113 JNJ-4496 JPM Healthcare Conference JPMHC JPY JS005 JUST-AAV Jack Phillips Jacobio Pharma Jacqueline Corrigan-Curay Jaguar Gene Therapy Jake Leach James Jamie Jan Hillson Janssen Janssen Vaccines January 2026 Janus kinase 1 Jascayd Jason Litten Jeavons syndrome Jefferies Jeito Jeremy Shefner Jerome Jersey pharma Jersey site Jesper Jian Jiangsu Hengrui Jigani Facility Jim Lang Jim O'Neill Jiwan Joaquin Job Development John Carroll Johnson & Johnson Intra-Cellular Joint Atomic Model Jon Congleton Jonmark Jorge Bartolome June Junshi Juvenile KARDIA-3 KAT5 wt Allele KB801 KCNT1 gene KER-0193 KEYNOTE-671 KEYNOTE-689 trial KEYNOTE-B96 trial KINECT-DCP KIT KKR KMT2A gene KOL KOMET-017 KP.2 strain KPI-012 KRAS KRAS NP_004976.2:p.G12C KRSA-028 Kaerus Kai Beckmann KaiSR Kainova Therapeutics Kaken KalVista Kala Bio Kane Biotech Karen Massey Karen Smith Karin Conde-Knape Karyopharm Therapeutics Kate Estep Kate Walsh Keir Starmer Keith Kelonia Therapeutics Kelun-Biotech Ken Paxton Ken Song Kendall Square Kennedy 's Kenneth W. O’Keefe Keren Leshem Kerry Dailey Kevin Hardage Keytruda Qlex Keytruda SC Keytruda head-to-head trial Keytruda patent Kezar Life Sciences Khalid Nabilsi Kidney Kidney Failure Kidney Failure, Acute Kidney Failure, Chronic Kim Kin-Hung Peony Yu Kinase Assay Kits Kinaset Kinevant Kissei Kit device Kite Pharma partnership Kite, device (physical object) Klaas Zuideveld Kleiner Knee pain Kong Korean language Korsana Biosciences Kostaive Kowa Krazati Kresladi Kristin Bittenbender Kriya Kronos Kronos Bio Krystal Biotech Kumquat Biosciences Kura Oncology Kv7 activator Kyle LaHucik Kymab Kymera Therapeutics LAVA-1266 LBCL LBP LDLR gene LEAD platform LEAP2MONO LENZ LGBTQ+ professionals LIGAND-AI LLM-based technology LOTIS-7 LP.8.1 sublineage LRP4 gene LRPAP1 gene LUCE-1 LUNA 3 trial LX9851 LYT 100 LaNova Medicines Labor (Childbirth) Lancet Landscapes Languages Larix Lark Health LarkVantage Lars Rebien Sørensen Larsucosterol Latex Fixation Tests Latigo Latozinemab Launch-HTN Lawrenceville Leaked Lean Derisking Leber congenital amaurosis-4 Leerink Partners Legal Case Legal Challenges Legend Biotech Lehigh Valley LensAI Lenvima Lepodisiran Lesion Letitia James Leukocyte adhesion deficiency type 1 Leukoencephalopathy, Progressive Multifocal Lewy bodies Libertas Bio Libertyville Illinois License Agreement Life Life Biosciences LifeMD LifeMine LifeSignals Lifespan Extension Lifetech Lilly 's Lilly partnership Limitation Limited stage (cancer stage) LinusBio Lipid Metabolism Disorders Lipids Lipoidosis Lipoprotein(a ) Lithotripsy Livdelzi Live - Specimen Condition Live Biotherapeutic Product Liver and Intrahepatic Biliary Tract Carcinoma Liver carcinoma Liver damage Loan Logica London Bioscience Innovation Centre London Cancer Long-Term Strategy Longwood Fund Lorbrena Lorundrostat Losers Lotte Lower Profile Lower Rates Lp(a ) drug Lukácsháza Luma Health Lumakras Lumina 3D Lumryz LunAIRo Lung Diseases, Interstitial Lung consolidation Lung-201 Lunit Lunit AI Lunit SCOPE Lunsumio Lupus Erythematosus, Cutaneous Lupus treatment Lutathera Lutetium-177 Lyell Immunopharma Lymphatic Abnormalities Lymphocyte Count measurement Lymphocytes Lymphocytes, Tumor-Infiltrating Lymphodepletion Therapy Lymphohistiocytosis Lynk Lynozyfic Lyophilized Inactivated Group A Streptococcus TARA-002 Lysosomal Storage Diseases M financing M growth fund M&A consolidation M&A transactions M.D. M6495 MACE-3 MADRS score MAGNITUDE-2 MASLD MC4R MCED MDASE MDD MDM2 Antagonist ASTX295 MDNA11 MDNA113 MDR CE Mark MEERKAT trial MESA MET exon 14 skipping mutation MET protein MIRACLE trial MIT MITIGATE trial MMRV vaccine MOG antibody disease MR closure MR-139 MRD MRM Health MSH5 gene MTLE MWT MYO7A gene MaGic trial MacTel Machado-Joseph Disease Macular retinal edema Madness Madrigal Magnet <device> Magnetocardiography Mahery Maintenance study Major Depressive Disorder Maker (occupation) Malignant Bone Neoplasm Malignant Female Reproductive System Neoplasm Malignant neoplasm of cardioesophageal junction of stomach Malignant neoplasm of endometrium Malignant neoplasm of thyroid Malus domestica Manfidokimab Manifold Bio Manihot esculenta MannKind Mantelli Mantle cell lymphoma Manufactured Supplies Manufacturer Manufacturing costs Marcel Reichen Marco Rubio Marengo Maria C. Freire Marietta Pennsylvania Mark McLellan Mark Pavao Mark Stevenson Markers (device) Martes pennanti Martin Martin Makary Mary-Elizabeth MassBio Massachusetts biotech Massive Mastermind Platform Mastocytosis, Systemic Matchpoint Therapeutics Matt Buckham Matt Skelton Mayne Mayo Clinic Mazdutide Measurement Mechanism (attribute) MedSurg MediKarma MediView MediView XR MediView XR90 Median Technologies Medicaid block grants Medicaid fraud Medical Imaging Medical Records Medical pathologist Medicare coverage Medicare drug prices Medicare fraud Medicare reforms Medicenna MedisourceRx Medivis Medtronic Megadeals Megarounds MeiraGTx Meister Melanie Ivarsson Melanoma TRP2 CTL Epitope Vaccine SCIB1 MenABCWY Menopausal symptom Menstruation Mental association Mentorships Merck 's Merck Verona Mereo BioPharma Mersana Metagenomi Metals Metapneumovirus Metastasis from malignant neoplasm of colon and/or rectum Metastatic Pancreatic Ductal Adenocarcinoma Metastatic Prostate Carcinoma Metastatic to Metis people Metric (substance) Michael Bierl Michael Chou Michael Houghton Michael Kott Michael Langer Michael Rogers Microbial Microbiome SER-155 Microbiome therapeutics Microsoft Discovery Microsoft Teams Mikael Mikael Dolsten Mikaela Naylon Give Kids a Mike Hershkovitz Mike Stuart Mild cognitive disorder Milestone Miller Dieker syndrome MindWalk Holdings Corp. Minder system Mindpeak Mineralys Minghui Minimal Residual Disease Negativity Ministry of Health Minxiang Zeng Mirum Misleading Drug Ads Missing Mitchel Berger Mitigation Strategy Mitochondrial Diseases Mitsubishi Mitsubishi Tanabe Pharma MoSEIC Modernization Modeyso Modic Mohammed Molecular Clamp technology Molecular Gates Molecular Imaging Molecular Targets Moleculin Monarez Monte Montes Montgomery County Montgomery-Åsberg Depression Rating Scale Month of May MoonLake Immunotherapeutics Morbidity - disease rate Morgan Stanley Morristown Mother (person) Mourenx Movantik Move GBS Forward™ Movement Mucopolysaccharidosis I Mucopolysaccharidosis III Multiomics Multiple Sulfatase Deficiency Disease Mumps Munich Regional Court Mural Mural Oncology Muscarinic Agonists Muscle Tissue Muscle-Boosting Drugs Musk MyPhenome Mycobacterium tuberculosis Myeloid Progenitor Cells Myocardial Infarction Myositis Myotonic Dystrophy Myqorzo N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide NAION NBI-1070770 NDA filing NEFL gene NEO100 NEPTUNUS-1 NEPTUNUS-2 NEREUS NGM NGN-401 NHS England NHS trial NHS-Galleri trial NIH grant NIH layoffs NINL gene NK1/NK3 receptors NKTX NLRP3 inhibitor NON Mouse NP-MP1 NPDR NPM1 gene NPM1-mutant NR1H4 gene NR4A2 gene NRG NTHI NUCLIDIUM NUSAP1 gene NUZ-001 NVG-291 NVIDIA 's NX-3911 Nabla Bio Nach01 Namandjé Bumpus NanoDisc NanoPhoria Nanobody Discovery Platform Nanostructured Materials Nasal Polyps Nasal drug delivery Nasal inflammation Nasdaq Stockholm Nasua Natera National Association of National Cancer Institute National Resilience National Security Commission Nature Aging NeOnc Technologies Nebulizers Negative Predictive Value of Diagnostic Test Negotiation Program Neko Health Nelson Sun ; Chief Operating Officer Nemluvio Nemvaleukin Alfa Neo-1 Neoantigen Neomorph Neoplasm Metastasis Neoplasm, Residual NervGen Pharma Neural Network Simulation NeuralPLexer Neuregulins Neurimmune Neuro Disease Neurodegeneration Due To Cerebral Folate Transport Deficiency Neuroendocrine Tumors Neurogene Neuromyelitis Optica Neuropsychology Neurosteroids Neurostimulation procedures of spinal cord tissue Neurotrophic keratitis Nevada Nevada <Geographic Area> New Approach Methodologies New Jersey operations New York AG New York Stock Exchange New-onset refractory status epilepticus NewAmsterdam NewBridge Pharmaceuticals NewCo NewLimit Newborn NewcelX Nexplanon NextCure NextRNA Nextstellis NiKang Therapeutics Nia Tatsis Nick Vatakis Nicole Verdun Nimacimab Nimbus Nipocalimab Nominee Non-Hormonal Non-Incretin Non-Muscle Non-Opioid Non-Opioid Pain Nona Biosciences Nonalcoholic Steatohepatitis Noninvasive Endpoint Noom Nordisk alliance Nordisk facility North Chicago North Chicago Illinois Nosis Novartis-Chinook acquisition November 2025 NovoCare Nubeqa Nucleus RadioPharma Numab Nuvation Nuvation Bio Nuzolvence OBT OCT50 OFA OIG bulletin OKYO OLN324 OMass ONWARD OPKO OPTIMA trial ORN-252 OSE Immunotherapeutics OTOF gene OTX-201 OX40 receptor OXPHOS pathway OXTR gene Obesity Drugs Obesity Trial Obesity care Obstructed Ocaliva Occupational activity of managing finances Oceanside Ocedurenone Ocrevus October Ocular Therapeutix OdyssION platform Office Officer David Rose Offit Ogilvy Health Ohtuvayre Ollin Ollin Biosciences Omeros Corporation Omicron Omicron JN.1 Omniverse On-Demand Webinars Onapgo Oncoinvent ASA Oncologic Drugs Advisory Committee Oncology Collaboration Oncology Focus OpenFold3 Operating Operating expenses Operational streamlining Opfolda Ophthalmological implant Opioid Opioid Crisis Opioid Use Disorder Opportunity Fund III Opthea Opthea 's Opthea layoffs Optigo Biotherapeutics OptimiZe technology Optimism Optinose Optogenetic Gene Therapy Opvee divestiture Oracle Health Oral Medicine Oral Wegovy Oral region Orals Orano Orbital Therapeutics Orca Bio Orca-T. Order Tubulidentata (organism) Organ Shortage Organisation for Economic Co-Operation and Development Organon Organovo Orionis Biosciences Orna Therapeutics Ornithine carbamoyltransferase deficiency Orotecan Orphan Cures Act Orthopedics Orum Therapeutics Oslo Stock Exchange Osteogenesis Imperfecta Osteoporosis Otsuka 's Otsuka Holdings Otsuka Pharmaceutical Oura Ring Outlook Therapeutics ' Outsourcing Ovation.io Overweight Ownership Oxervate Oxford BioTherapeutics Oxford Finance Oxford spinout Oxycontin P-Value PADOVA study PALSONIFY PB212 PBA PBMs PC Platform PCED PCSK9 protein, human PCVs PD-1xVEGF bispecific PD-L1xVEGF-A PDE3/4 inhibitor PDUFA VIII PERIDOT PERSEUS trial PET/CT scan PF-06954522 PF-08653944 PF-ILDs PFAS gene PFS PGI PHD inhibitor PI3 K inhibitors PI3 K pathway PIK3CA gene PIK3CA mutation PIK3CA/AKT1/PTEN pathway PIPE financing PIVOT-PO trial PKMYT1 protein, human PKP2-associated cardiomyopathy PLK1 gene PMN310 POETYK PP353 PRECISE-AD trial PREVAIL trial PRISM BioLab PROSERA PROTACs PRV PRX012 PSMA-targeting PTAB PTEN-deficient tumors PTH1R gene PTK7 PTK7 protein, human PURPOSE studies PWS PYNNACLE trial Pacira Pacira BioSciences Pain Palvella Therapeutics Palynziq Pancreatitis, Acute Pandion Parabilis Medicines Paragon Therapeutics Paratek Parker Institute for Cancer Immunotherapy Parkinson 's Paroxysmal nocturnal hemoglobinuria Paroxysmal supraventricular tachycardia Part B drugs Participant Partnering Pasadena Patent extension PathAI Patient Protection and Affordable Care Act Patient data Patient location type - Department Patient-Centered Patrick Vink Patrizia Cavazzoni Paul Edick Paul Fornazzari Paul McKenzie Pavblu Payspan Pazdur Pediatrics Peer-Reviewed Research Pelage Pelage Pharmaceuticals Pemgarda Pemphigus Vulgaris Pennsylvania site closure PepMetics Perianal fistula Peripheral Arterial Diseases Peripheral neuropathic pain Peripheral neuropathy due to and following antineoplastic therapy Perjeta Perkins Permanent Peroxisome Proliferator-Activated Receptors Persica Persistent Personality Character Personalized Persons Perspective Pet Animal Peyronie 's disease Pfizer 's Pfizer Ventures Pfizer acquisition Pfizer staff Pfizer vet Pfizer-BioNTech Phagocytosis Pharma AI Pharma Acquisition Pharma Concessions Pharma Tariffs Pharma import taxes Pharmaceutical Group Pharmaceutical Ingredients Reserve Pharmaceutical Layoffs Pharmaceutical Packaging Pharmaceutical Policy Pharmaceutical executive pay Pharmacogenomics Phase Phase 1 - 2a Phase 1/2 trial Phase 1/2a Phase 2 BEACON Phase 2 Failure Phase 2 VALIANT Phase 2 termination Phase 2a Trial Phase 2b SYMMETRY Phase 2b trial Phase 3 COMPETE trial Phase 3 CREST trial Phase 3 INDIGO Phase 3 INDIGO trial Phase 3 PIVOT-PO trial Phase 3 RINGSIDE trial Phase 3 planning Phase 3 prospects Phase 3 readiness Phase I – III study Phase II Phase II Failure Phase II data Phase III AURORA trial Phase III Essence study Phase III MAGNITUDE trial Phase III MARIPOSA trial Phase III REGENCY trial Phase III ZENITH trial Phase IIa Phenylketonurias Philips Phoenix Arizona Photoimmunotherapy Physical AI Physical activity Physical and emotional exhaustion state Physician Executives Physicians PiNACLE Pick Disease of the Brain Piclidenoson Pilatus Pill Penalty Pioneer Antibody Discovery Pioneering Medicines Pipeline Review Pipeline Strategy Pirtobrutinib Pitch - substance Pivotal Pivotal Trial Plants Plaque (lesion) Plexiform Neurofibroma Pliability Plozasiran Pluri Pluvicto Poisons Pol Theta Polaryx Therapeutics Polpharma Biologics Polycythemia Polyradiculoneuropathy Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Pombiliti + Pooled Sample Portfolio diversification Positive Post-Pandemic Downsizing Post-bankruptcy consolidation Post-marketing study Practice Experience Prasad 's Prasinezumab Pre-Exposure Prophylaxis Pre-filled Syringe Prealbumin Precision Diagnostics Precision Imaging Network PrecisionLife Predict Pregnanolone Premier Inc. Prescription Drug Overuse Presidential Symposium Preventive Health Programs Previous Primary hyperoxaluria Principles Priority Review Voucher Private financing ProFound Therapeutics ProMIS Neurosciences Proactive Health Probiotics Problem Professional guide Progestins Progranulins Projections Promotion (action) Prompts Protara Therapeutics Protection Protein Kinase C Protein Kinase C Inhibitor Protein Purification Protein, Organized by Structure Protein-Protein Interaction Proto-Oncogene Proteins c-akt Protoporphyrin IX Provider Proximity Prurigo PsA-2 trial PsCatCh2.0 Pseudobulbar affect PsiThera Psoriasis Area and Severity Index Clinical Classification Psoriatic PsyLabs Psyence BioMed Public Health Trust Public Listing Pulmonary Eosinophilia Pulmonary artery pressure Pulmonary veins Purchase Purchased Services, Clinical and Biomedical, Calibration, Laboratory Purchased Services, Clinical and Biomedical, Research Purchased Services, Staffing, Supply Chain Purdue PureTech Purpura, Thrombotic Thrombocytopenic Put Option Agreement Pyoderma Gangrenosum Pyzchiva Q-Scientist Q1 2026 Q1 trends Q2 layoff Q2 sales Q4 FY2025 QIAGEN QLS-111 QUC398 Qilu Pharmaceutical Qlaris Bio QuEEN Qualification QuanBio Quantori Quviviq R&D shutdown R&D strategy RAS cancer RAS inhibitors RAS-addicted cancers RAS-mutated RAS/RAF inhibitor RCT RDX-002 RE104 REACH-DMD study REACtiVe-2 RENOIR REVEAL-1 REZOLVE-AA REZOLVE-AD RFK Jr. rhetoric RFK Kennedy RIFs RIPK2 RIPK2 scaffolding inhibitor RNA Splicing RNA Vaccine RNA delivery RNA drug RNA gene RNA medicine RNA medicines RNA obesity RNA technology RNA test RNA therapies RNA-LNP RNA-targeted medicine RNA-targeting RNAi medicine RNAi medicines ROR1 protein ROR1 protein, human ROS1 gene ROS1-positive Lung Cancer ROS1-positive NSCLC ROSA Knee RRP RSNA RSV antibodies RSV vaccine RTU cartridges RTW RV-8451 RVO RVU120 RWE RZLT Rachael Racism Radar Therapeutics Radiance Biopharma Radicava Radiology Specialty Radionuclide therapy Radspherin Rahway Raised Rakuten Medical Rallybio RLYB212 Randomized Controlled Trials as Topic Rani Therapeutics Rapid Edge Cloud RapidAI Rating (action) Ratio Therapeutics Readiness Reading (activity) ReadyFlow Autoinjector Rebeca Villarreal-Barragan Receptors, Islet Amyloid Polypeptide Reciprocal Recognify Life Sciences Recovery - action Recurrence Risk Recursion Pharmaceuticals Reflex Refractory Plasma Cell Myeloma Regeneron Pharmaceuticals Regulation of biological process Regulatory Authority Regulatory Crackdown Regulatory Expertise Regulatory Framework Regulatory Impact Regulatory Path Regulatory Pathway Regulatory T-Lymphocytes Reindeer Reinvention Relapse Relapsed/Refractory Relative (related person) Relay Device Relieving Religious Missions Relmada Relyvrio Remote Internship Remote control command - Clear Renal Cell Carcinoma Renal function Renalys Rentschler Rentschler Biopharma Repare Reperio Health Report (document) Research Infrastructure Research Organization Research Projects, R-Series Research Triangle Park Reshma Kewalramani Resistance (Psychotherapeutic) Resistant hypertensive disorder Resources Restricted Resumption Retifanlimab Retinoschisis Retreatments Retrotransposons Return to (contextual qualifier) (qualifier value) Reunion Reunion Island Revenue Milestone Reverba Global Reverse Stock Split Revita Reviva Pharmaceuticals Revolution Vibe CT Revuforj Rezatapopt Rezolute Rezon Bio Rezurock Rhode Island Rhythm Rhythm Pharmaceuticals Ribo Ribupatide Richard Richard Fair Richard Gonzalez Richmond Rick Fair Rick Osterloh Ridgefield New Jersey Rinvoq growth Risdiplam Rise Up trial Risk Management Rivus Pharmaceuticals Rob Michael compensation Rob Pinataro Robert Kramer Robert Michael Robert Warner Roche 's Roche Diagnostics North America Rocket Pharmaceuticals Roctavian Roger Perlmutter Roivant Sciences Ronde-cel Roopal Ross Haghighat Rotation Round three Royalty Pharma Royalty-Driven Model Rubella Russia Russian language Ryan Richardson Ryvu Rznomics SABCS25 SAFEbody technology SALT score * * SANDCAT trial SAT-3247 SAVITRI SB-01 SBA SBX sequencing SC0062 SCLC SCN10A gene SCN2A mutations SCOPE IO SCOPE trial SCOTUS SEC SEP-786 SERENA-6 trial SERON SGR-2921 SGT-003 SHP-DB1 SIK2 gene SIM0505 SIM0709 SITC SKB105 SLC17A5 gene SLC6A8 Inhibitor RGX-202 SLL SLTE-1009 SLV-154 SLV-324 SMA SOHO SOL-1 SOLAIRIA-1 SOLAIRIA-2 SOLSTICE SPAG8 gene SPG302 SPS SPaL SRP-1003 SRP-9003 SRSD107 SSGJ-707 STAR-221 STAT6 STAT6 protein STELLAR-303 trial STI-based STOMP2 STX-001 STXBP1 gene SURMOUNT-5 Trial SURPASS-CVOT SURPASS-PEDS SURVEY.ALSFRSR SV Health Investors SVP SYD-101 SYMPHONY-1 trial SYNC-T Sabeen Mekan Sackler family SafeBeing platform Safety Issues Safety labeling Sagimet Sail Biomedicines Sailaja Battula Sales growth Samit Samsara Samsung Bio San Diego San Rafael Sanacor Sanjay Sanjula Jain-Nagpal Sanofi Blueprint Medicines Sanofi Strategic Sanofi Ventures Sanofi acquisition Santen Santé Ventures Sapablursen Sapio Sapio Sciences Sarah Boyce Sarbani Sarcoidosis, Pulmonary Sasanlimab Satellos Scancell Scemblix Scheme of Arrangement Schott Schweizerhalle Science of genetics Scientific Data Scientific Sessions Scientific Study ScinoPharm Sciwind Sciwind Biosciences Scorpions Scott Howell Screens (device) Scripps Research Seagen acquisition Sebetralstat Secondary malignant neoplasm of pancreas Section 232 Sector Security Measures See-Mode Selective Estrogen Receptor Down Regulator Self-Injectable Self-injection Self-pay Semerjian Senators Senile cardiac amyloidosis Seno Medical Sensorineural Hearing Loss (disorder) Sentynl September 23 Sequestration Seralutinib Serbs Seres Sergio Marullo di Condojanni Series B fundraising Series C Series C financing Series C funding Series D1 Series E funding Series F Series F financing Serine/Threonine Kinases Seronegative Sevaro Health ShORe Shankar Ramaswamy Shapes Shareholder Ownership Structure Shareholders Meeting SheMed Sherwin Sattarzadeh Shield Shigella Infections Shigella Vaccines Shin Ashida Shingrix competitor Ships Shock Shooting sensation quality Short Bowel Syndrome Shortened Sialic Acid Binding Immunoglobulin-like Lectins Sickle Cell Siemens Healthineers Signal Signal Transduction Signatera Simplexvirus Simufilam Single Agent Therapy Single-Domain Antibodies Sirexatamab Sirius Sirona Medical Sironax Sitala Site Closure Site of exit Sjögren 's disease SkyEngine Skyrizi Slate Medicines Sleep Apnea, Obstructive Sleep Disorders Sleep disturbances Sleep medicine specialist Sleeplessness Smoldering myeloma Sobi Social Media Society for Neuro-Oncology Software as a Medical Device Solid Biosciences Solutions Solve Therapeutics Solventum SomaLogic Somatix Sotatercept South Korean biotech South San Francisco Sparrow Pharmaceuticals Spatial Mosaic Specialty pharma Spectrum Profiling Spero Therapeutics Spevigo Spine BioPharma Spinogenix Spiriva Respimat Spondylarthritis Spravato Spring Health SpyGlass Pharma ( SpyLock technology SpyTag/SpyCatcher Squamous cell carcinoma Squamous cell carcinoma of skin Squibb Layoffs Squibb partnership Stabilization Standard BioTools Staphylococcus aureus Star Therapeutics Stargardt's disease State Room Statement Status Quo Stein facility Stemchymal Step Pharma Stephen Hemsley Stephen P. Dale Steve La Neve Steve St. Onge Steve Tomlin Stevenage facility closure Stiff-Person Syndrome Stimulation procedure Stivarga Stock Reaction Stoke Stoke Therapeutics Strategic Deals Strategic Growth Strategy Strive Pharmacy Structure of hippocampal commissure Stuart Pharmaceuticals Stéphane Bancel Subcutaneous Cancer Sublocade Subsidies Substance Abuse Detection Substance with human epidermal growth factor receptor 2 inhibitor mechanism of action (substance) Substance with programmed cell death protein 1 inhibitor mechanism of action (substance) Summer Sun Pharma SunRISe-1 trial Suneet Varma Sunita Mishra Super Bowl 2025 Super Bowl ads Superluminal Medicines Supernus Supervisory Board Supply chain disruption Support Services Program Supranuclear paralysis Supreme Court stay Surgeon Surgical Replantation Surrogate Susan Susvimo Sutro Suvretta Capital Management Suzanne Winter SwiftFluo Swissmedic Swixx Group Sydnexis Syfovre Sylvia Isler Symptomatic SynAIRgy Synapse AI Synbio International Inc. Syncromune Syndax Syndeio Synthetic Lethality Syphilis, Congenital SystImmune T business T-cell malignancies T-cell therapy TAF8 wt Allele TAILORED-AF TAK-861 TALAPRO-2 TAS-205 TB Alliance TCEs TCR TCR-NK cell therapy TECVAYLI TECregen TESARO TETON-2 THB335 THETA platform TIDAL-01 TIGIT antibody TLN-121 TLN-254 TLN-372 TLX2 gene TNFRSF4 gene TOGETHER-PsO TPRG1L gene TR-FRET TRANSCRIPTION FACTOR TRBV9 gene TREX1 gene TRICORDER TRIM21 TRIMTAC TRONTIER TRPC6 inhibitor TRPV4 protein, human TRiM platform TSHA-102 TSND-201 TScan Therapeutics TTAM TTR wt Allele TULIP-SC trial TYK2 Inhibitor Tablet Dosage Form TaiGen Biotechnology Taiwan Takeo Takhzyro Taltz Tampa Florida Tanabe Pharma Tang Tanruprubart Tavneos Taxes Taysha Gene Therapies Tazverik Team Tech Rivalry TechLive Ted Love Tedopi Teijin Teladoc Television Telix Tender Tenvie Tepkinly Termination - Inactive Reason Code TerraBind Terry Fox Research Institute Testiculo- Testing Texas Facility Texas Tech Thad Huston Thakkar Theranostics Therapeutic Antibody Theravance Biopharma Thick Third Circuit Court Third Harmonic Bio liquidation Third line treatment Thomson Reuters Thousand Oaks Thrombotic Stroke Thyme Care Thyroid Diseases Tidmarsh Tim Van Hauwermeiren Tiragolumab Titles Tiziana Life Sciences Tonix Tonmya Topco Toru Ashida Total Improvement Score Tourette 's syndrome Tourmaline Bio Toxic Epidermal Necrolysis Toxic Oligomers TraceNET Tracer Tracy Beth Heg Trail Making Test Transcarent Transfection Transfer RNA Transformational Data Transforming RNA Medicine Development Transplantation Transposition of Great Vessels Trastuzumab Rezetecan Travel Health Treating Treatment Adherence Treatment Effectiveness Tregs Tremfya TriNetX Trial Phase Trial Termination Trimonthly Trinity (ethnic group) TruTCR Trump 's Trump administration reforms Trump administration tariffs Trump drug pricing Trump import tariffs Trump tariff Trust (Social Behavior) Truvada Truveta report Tukysa Tumor Microenvironment Tumor Suppression Tumor board Tumor stage Tis Tumor-Infiltrating Tumorigenicity Turitz Tyruko Tysabri Tyvaso Tzield U.S. Food and Drug Administration UAE UBT251 UCB UCCD UK 's UNLOXCYT UPB UPCR US-China competition US-EU UgeneX Ugur Sahin Undetectable Unicorn births United Imaging Healthcare United Laboratories International Holdings Limited United States Agency for International Development Universal University of California Unnatural Products Unravel Unspecified Abortion Updates Upstream Bio Uptake Urcosimod Urinary Bladder Urinary hesitation Urine culture Urology Urticaria Urticaria due to cold Usher Syndrome Type 1B Uwe Buecheler VAL-413 VALOR study VAV1 protein VAX-24 VAX-31 VAY736 VAYHIT2 trial VDPHL-01 VENT-02 VENT-03 VESALIUS-CV trial VESPER-3 VGA039 VHH VHH Immunoglobulin Fragments VIKTORIA-1 VIZZ VMAT2 Inhibitor VMX-C001 VRDN-003 VTCN1 gene VX-993 VY9323 VYJUVEK Vaccination Hesitancy Vaccine Reform Vaccine Testing Vaginal Microbiome Valiltramiprosate Valinor Vamikibart Vanda Vanderbilt University Medical Center Vanrafia VantAI Variant Variant Bio Variation (Genetics) VarmX Vas Narasimhan Vaseline Vasudev Bailey Vaxcyte VectorY Veklury VelaVigo Vemircopan Venclexta Ventana Medical Systems * * Veraxa Verification Verily Versant Vertex Veru Verzenio Vestibulo-Ocular Vevzuo ViVac Pharma Viable Viatris Vibrance-1 study Vicebio ViewPoint EchoPilot Viewer Device Vigil Neuroscience Vimseltinib Vinay Prasad FDA memo Vincentage Vineet Agrawal Violence Viome Virginia Virginia facility Virginia plant Viridian Virtual Geneticist Virus-Like Particle Visible Vision Restoration Vistagen Visual Suppression Visugromab Vital capacity test Vivtex Voluntary Scheme Vomiting Vor Bio Voucher Voyxact Vunakizumab Vyglxia Vykat Vykat XR Vyvanse Vyvgart Hytrulo WARN WARN filing WARN notice WEE1 WEE1 gene WEE1 inhibitor WHIM syndrome WP1066 WVE-N531 Wakefulness Test Walmart partnership War-Lock platform Warsaw-Duchnice Washington state WeDosify Wearable Behavior Model Wearable Electronic Devices Web Site Weldon Weldon 's Welfare Welireg Wellcovorin Werner Syndrome Werner helicase Western biotech Western patients Wet AMD Wet Age-Related Macular Degeneration White House liaison William Blair Wilmington Wolfgang Wienand Women Workforce Working Group World WorldMeds Wounds - qualifier Written - Consent Mode Wuhu X-Linked X-linked retinitis pigmentosa XHANCE XLRP XOMA Royalty XR Xanthomatosis Xarelto Xarelto patent Xenograft procedure Xenon Pharmaceuticals ' Xevinapant Xianweiying Xolremdi Xspray Pharma XtalPi Y-mAbs Y220C mutation YB-101 YUVIWEL Yarrow Bioscience Yervoy Yidafan Yosemite Young Adult Yupelri Yvonne Greenstreet Z-1018 ZENITH trial ZG006 ZI-MA4 ZIMA-101 ZM-02 ZUSDURI ZW171 ZYCUBO Zai Lab Zaka Zami Aberman Zanidatamab Zelgen Zelis Zelluna Zemaira ZenGUARD Zentalis Zentek Zepzelca Zervimesine Zhongmou Zilebesiran Zilganersen Zilovertamab Zimmer Biomet Zongertinib Zonsen PepLib Zoë Zuellig Pharma Zydus Lifesciences Zynyz aDBS aGvHD aTyr abelacimab acasunlimab access strategy accessible aceclidine acquisition talks acquisition termination active pharmaceutical ingredients activin signaling acute graft acute systemic infection ad campaign adaptive deep brain stimulation adaptive dosing adjunctive treatment adjuvant Tecentriq adjuvant setting adjuvant treatment administrative law administrative proceedings adulteration advanced breast cancer advanced manufacturing advisory affairs aflibercept age restriction age-related diseases agency departures agency instability agency staffing shortages aging-related diseases all-cash tender alliance allogeneic hematopoietic stem cell transplant with purging alpha opportunities alpha radioligand therapies alpha radiopharmaceutical alpha-synuclein antibody alternative testing alternatives ambulatory care services amezalpat amivantamab ampreloxetine amsacrine/azacitidine/etoposide amycretin amyloid beta antibody amyloid-beta amyloid-lowering drug anaphylaxis anifrolumab anitocabtagene autoleucel annamycin anti-APRIL antibody anti-IgE anti-TL1A anti-TSHR antibody anti-VEGF therapy anti-amyloid antibody anti-fibrotic anti-vaccine movement antibody candidates antibody collaboration antibody design antibody engineering antibody-chopping drug antisemitism antisense antithrombin III antitrust lawsuit antitrust litigation apatinib apecotrep apomorphine hydrochloride applicability application assessment appropriations approval status aroxybutynin artemether-lumefantrine artificial luciferases aseptic manufacturing asset termination assumes assurance at-home at-home colon cancer at-home screening at-home treatment ataluren atlases atomoxetine attractiveness auction autoimmune drugs autonomous avibactam azacitidine azetukalner aztreonam b.well partnership backer baldness cure bankruptcy filing belumosudil bemarituzumab benefit-risk profile bespoke bevacizumab bile acid therapy biliary cholangitis bimagrumab bimatoprost IOL biochemical recurrence bioequivalence bioequivalence testing biofilm-driven chronic respiratory disease biologic blockbusters biomanufacturing jobs biomarker qualification biomarker test biomarker testing biomedical foundation models biomedical innovation biomolecular structure prediction biopharma exit strategy biopharma financing biopharma industry biopharma job biopharma regulation biopharma startups biopharma survey biopharmaceutical company biopharmaceutical innovation biopharmaceutical partnership biopharmaceutical sector biopharmaceutical startups bioprocess bioprocessing biosimilar competition biosimilar guidance biosimilarity biosimilars approval biotech careers biotech closure biotech collaborations biotech dealmaking biotech employment biotech executive biotech finance biotech financing biotech incubator biotech leadership biotech licensing biotech pivot biotech spinoff biotech strategy biotech workforce biotechnology innovation biotechnology layoffs biotechnology partnerships bipartisan criticism bird flu vaccine birtamimab birth dose bispecific antibody screening bispecific antibody technology black-box warning blockbuster drug blockbuster drugs blockbuster sales blocker blood clotting drug blood pressure ambulatory blood sugar control board members board shake-up bone lesion prevention boost booth bortezomib bota-vec brain fluid brain shuttles brain volume brain-penetrant brain-penetrant delivery brand-name drugs brand-name prescriptions branded medicines broaden business options business practices business split business strategy business unit butyrophilin superfamily cGAS inhibitor cGVHD cUTIs cabotegravir calcium camizestrant campaign campaigns cancellations cancer antigen therapy cancer intelligence cancer prediction cancer research trends cancer testing cancer therapeutics cancer treatments cancer trials capacity quadruple capital constraints capital investment capivasertib capsule (pharmacologic) cardiac research cardiac safety cardiometabolic care cardiometabolic disease cardiorenal medicine cardiotoxicity screening cardiovascular asset cardiovascular benefits cardiovascular gene therapy cardiovascular safety cardiovascular trial cargo receptor ligand activity cartilage degradation carve-out casdatifan cash-paying cell analysis cell classification cell therapy manufacturing cell therapy sale cell therapy sales cell transfer cell transformation cell-associated neurotoxicity cell-device combo cell/gene therapy cellular rejuvenation cemdisiran central reads central subfield cerebrotendinous xanthomatosis chairman resignation charmed checkpoint inhibitor-resistant chemical alternatives chemical space chemo-displacement chemo-turned-gel drug chemotherapy-free regimen chenodeoxycholic acid childhood health chinese medicine cholesterol ester transfer protein inhibitor cholesterol-lowering choline chronic disease epidemic chronic disease management chronic graft-versus-host disease chronic health conditions chronic hives cisplatin-ineligible civil class action clawback rate clazakizumab clean sweep clemidsogene lanparvovec click clinic entry clinical AI clinical diagnostics clinical holds clinical operations clinical outcomes clinical remission clinical reproducibility clinical research services clinical results clinical seizure clinical strategy clinical terminology clinical trial conduct clinical trial design clinical trial halt clinical trial results clinical trial review clinical trial update clinical visualization clinical worsening clinical-stage clinical-stage AI startups clinical-stage assets clinical-stage biopharma clinical-stage biotech clinical-stage immunotherapy clinical-stage pharmaceutical clinicogenomics clofutriben clone stability closed-loop interventions co-development co-exclusive license co-location coalition cognition cognitive improvement cold chain logistics collaborative framework collaborative healthcare coloplast commercial supply chain commitment community grants companion diagnostic companion diagnostics company closure company transformation competitive weight loss medication competitiveness complement system compounding pharmacy computational drug discovery computational protein design concept concessions conditional approval pathway conditioning regimens confidentiality confirmatory study conservative criticism conspiracy constitutional challenge constitutionality content intelligence contextual errors contingent value contingent value rights continuous continuous glucose monitor contract cancellation contract extension contract manufacturer controllable controversy conversation convertible copper histidinate copper isotopes corneal endothelial disease coronary trial corporate development cost management cost-cutting initiatives cost-effectiveness cost-reduction cost-saving country-of-origin labeling covalent binding drugs covalent biologics covalent chemistry cranial neurosurgery crash craving control credit card fees critical bleeding cross-border pharma ctDNA-guided therapy customer-facing organization customs loophole cutaneous remission cyclic adenosine-5'-trimetaphosphate cyclobenzaprine cynicism cytisine daily pills daisy danegaptide daratumumab daridorexant data bottlenecks data manipulation data misinterpretation data modernization data secrecy data solutions data-driven decisions data-driven innovation dazucorilant de novo miniproteins deal activity deal termination death risk reduction debt debt maturity extension debt obligations deceptive marketing decision day decision delay decision science decitabine deficiencies degraders delgocitinib demerger dencatistat depression drug deprioritization deruxtecan-nxki device regulation diabetes care diagnostics industry digital enablement digital endpoints digital health records digital health regulation digital health screener digital infrastructure digital medicine digital quality systems digital solutions digital tools digital twin dimethylethylsilylimidazole direct-to-consumer ( DTC ) direct-to-employer director firing disability services disease activity disease control rate disease drug disease program disease therapies disease treatment disease-modifying treatment disorder control (procedure) distributor network divestiture dividend docetaxel domestic pharmaceutical industry domestic production domestic supply chain doravirine/islatravir dotinurad doubt downturn draft report drug activity drug ads drug affordability drug application drug approval outlook drug candidates drug competition drug conjugates drug delivery innovation drug delivery platform drug development pipeline drug development sentiment drug discontinuation drug discount program drug discounts drug failure drug import duties drug importation drug imports drug ingredients drug lag drug licensing drug manufacturers drug optimization drug pipeline drug price negotiation drug pricing plan drug production drug quality drug rebates drug relabeling drug reviews drug sales drug-resistant drug-resistant TB drug-resistant epilepsy drug-resistant focal seizures dry AMD dual pathway inhibition dual-payload technology dual-targeting dual-targeting CAR-T dulaglutide dupilumab eGenesis eRNA early disease early-phase trials early-stage trial earnings beat ecnoglutide efdoralprin alfa efimosfermin alfa efzofitimod elebsiran elecoglipron electronic health record - ActClassContainer elenestinib elinzanetant eloralintide emiltatug ledadotin employee layoffs employment employment reduction enLIGHTEN Discovery Platform enforcement letters enfortumab engine enlicitide decanoate enobosarm enrollment forms enrolment entera enterprise reorganization entry - ActRelationshipCheckpoint environmental enzyme engineering enzyme restoration enzyme technology eosinophil epigenetic modulator epigenetic therapy epinephrine equity buyback equity financing ersodetug esreboxetine estate estrogens etanercept etripamil evaluation event cycle evidence-based evolocumab exacerbations exagamglogene autotemcel exclusivity extension executive actions executive changes executive exits executive promotions executive survey executive team executive vice president executives exemptions existential threats expanded label expansions expedited pathway experts external control group external controls external partnerships extrahepatic RNAi eye treatment eyonis facilities facility closure facility consolidation factor XIIa factory closure fam-trastuzumab fantasy-romance farabursen faster fat loss federal agencies federal courts federal directives federal workers fee structure fentanyl fibrodysplasia fibrosing fidrisertib field ablation figures filing checklist final analysis financial guidance suspension financial outlook financial recovery financial strategy financial struggles financial troubles financing strategy finerenone firi-cel first-in-class antibiotic first-line maintenance fiscal flagship office flu/COVID-19 foreclosure proceedings foreign factories formula update formulary exclusion formulations four-letter suffix franchise fratricide-resistant full-year guidance function functional cure funding agreement funding bill funding environment funding lapse funding rounds gains gamma secretase inhibitor gamma-linolenic acid garadacimab-gxii gastric inhibitory polypeptide receptor gastroenteropancreatic neuroendocrine tumors gastrointestinal gedatolisib gemcitabine gemcitabine intravesical system gemcitabine releasing system gene modulation gene variants gene writing generative design generative models generic competition generic manufacturing genetic cell genetic diagnosis genetic medicines genital lesion reduction genome engineering genome screening genomic analysis genomic drug discovery genomic medicines genomics AI genotoxicity geopolitical risk gildeuretinol glatiramer acetate global commercialization global competitiveness global drug development global drug pipeline global expansion global growth strategy global headquarters global health programs global health security global license agreement global network global price global sales global strategic R&D center global strategic collaboration global strategic partnership global strategy global trade tensions global workforce reduction glycoengineering glycosylation go-to-market models goal golimumab government programs government review governmental engagement grace granite grant cancellation green energy green list green manufacturing gross profit growth drivers growth opportunities growth strategy guidance cut guidance raise guidance upgrade guidances gusacitinib hair loss treatment halt hand sensation harassment head-to-head trial headcount health coverage health data privacy health prediction health system partnerships health systems health tracking health workers healthcare AI healthcare agencies healthcare appointments healthcare benchmark healthcare budget healthcare changes healthcare finance healthcare financial performance healthcare legislation healthcare marketing trends healthcare operational healthcare operations healthcare payments healthcare workflow healthtech healthy lifespan healthy longevity heart drug height velocity hematologic cancers hematologic care hemoglobin response hemophilia A program hepatitis B policy change heroin herpesvirus 2, human high-performance computing high-throughput hold-and-kill homegrown hormone receptor-positive hospital intervention host disease huntingtin-lowering hyaluronidase hyperscaled data iMTP iRhythm iSCIB1 + iberdomide ibogaine icotrokinra illegal immigration iloperidone iluzanebart image management imaging AI immune compromise immune disorder therapy immune profiling immune protection immune system reprogramming immune-mediated diseases immuno-dermatology immunoglobulin G impairment charges implantable device implementing import rules import taxes in situ in vivo studies incretin secretagogue incretin therapy indictment individual choice individual-based decision-making induction trials infant infestation infigratinib influenza prevention infringement inhaled lung disease inidascamine initiation protocol innovation centre innovative drugs insider insider trading insolvency integrated solutions interferon pathway interleukin-11 interleukin-12 interleukin-23 interleukin-3 interleukin-4 intermediate-risk internal disagreement internal tensions international operations international pricing international trade internet phrase internship intisemeran intra-abdominal infections intraoperative guidance intrathecal delivery intrathecal formulation intravenous formula investing investment grants investor rescue investor sentiment islet isolator technology itolizumab ixekizumab ixovec iza-bren judgment jumping gene jurisdiction kickback scheme kidney drug kidney therapeutics kilobase pairs kinase inhibitor [EPC] kyron.bio label extension label update labeling change labeling changes laboratory modernization laboratory reform programme lack of lack of transparency lanifibranor large-scale manufacture laru-zova late-stage assets late-stage clinical development late-stage testing layoff leader leaders legal victory legality lender takeover lentiviral vector lentiviral vectors letrozole leucovorin leuprolide levacetylleucine license suspension licensing restrictions life science incubator life-extension life-saving medicine likeability linezolid listings live event liver enzyme elevation liver-targeted RNAi loan financing localization locally advanced head loncastuximab tesirine long-acting long-acting injectable long-acting injectables long-acting protection long-acting therapies long-acting therapy lorlatinib loss of function loss treatment lotiglipron low low-cost lung scarring lurbinectedin lymph nodes lymphocyte immune globulin, anti-thymocyte globulin lymphocyte-activation gene 3 protein lymphocyte-activation gene 3 protein, human mAbxience mCRC mCombriax mNEXSPIKE mRESVIA mRNA contracts mRNA misinformation mRNA production mRNA therapy mRNA-1083 mRNA-1283 mRNA-1647 cytomegalovirus vaccine mRNA-4359 mRNA-based mRNA-based Personalized Cancer Vaccine mRNA-4157 macrocyclic peptides macroeconomic macular maintenance trial management layers management technique mandates manufacturing capacity manufacturing challenges manufacturing consolidation manufacturing deficiencies manufacturing license manufacturing practice manufacturing shutdown manufacturing uncertainty marketing authorisation marketing officer marketplace marstacimab mast cell therapy match Eylea mazdutide measles, mumps, rubella, varicella vaccine measurable outcomes med-tech medical advancements medical breakthroughs medical device company medical documentation AI medical freedom medical groups medical leadership medical review medical supplies medical supply chain medical technology medical technology exemptions medtech industry meeting cancellation mega depots melanin-concentrating hormone membranoproliferative glomerulonephritis men 's health mental health innovation merger cancellation mesothelin metabolic dysfunction-associated steatohepatitis metabolic health metabolic medicines metagenomic sequencing mezigitamab microdosing microenvironment microparticle technology microservices mid-2030s mid-stage middle dose middle-income countries middlemen midline glioma midterm milestone payment milsaperidone milvexian mini-proteins minimis exemption minimization missed milestone mitazalimab mivelsiran molecular entities molecular residual disease month most-favored most-favored-nation pricing motor fluctuations motor milestones mouse models movers mucosal healing multi-agent system multi-agent systems multi-cancer early detection multi-cancer screening multi-institutional research multi-medicine platforms multi-omic strategies multi-payload multi-program collaboration multi-sensor multi-specific antibodies multi-year collaboration multibillion-dollar market multiforme multimodal AI multimodal data multiplex test muscle health muscle loss muscle strength endpoint muscle-invasive musculoskeletal conditions myosin inhibitor naloxegol naltrexone-bupropion naming convention nano-in-micro delivery nanobody nanodelivery nanoparticle delivery naproxen-n-butyl nitrate narmafotinib narsoplimab nation policy national priorities national priority review voucher national priority review vouchers national sector growth nations nature-inspired drug discovery navenibart negative opinion negotiators neladalkib nemolizumab neo-epitope cancer vaccine net income net sales neuro injury neuro pipeline neuro-metabolic diseases neuro-rare diseases neuro-specialty diseases neurofibroma neuropathic corneal pain neuroprotective neuropsychiatric drugs neuroscience division neurotechnology neurovascular AI neutrophil-mediated disease new product newco nexiguran nexiguran ziclumeran next-gen brain therapies next-generation Covid vaccine next-generation drugs next-generation sequencing next-generation vaccine nintedanib nipocalimab-aahu nirsevimab nizubaglustat nmHSPC nodularis nomination nomination committee non-European ancestry non-competitive profile non-cystic fibrosis bronchiectasis non-dilutive non-dilutive financing non-hormonal therapy non-incretin therapies non-inferiority non-mRNA vaccine non-metastatic non-opioid pain medication non-opioid pain relief non-opioid pain therapies non-relapsing secondary progressive non-surgical back pain noncirrhotic nonprofit webinars nonsurgical treatment options normative wakefulness nucleic acid delivery nusinersen oHCM obesity pill obesity therapy obesity trial obesity-related cancers ocular adverse events ocular immunology off-target offerings offloading older children oligomer selectivity omnichannel on-demand once-yearly oncology advancements oncology company oncology decisions oncology diagnostics oncology ecosystem oncology expert oncology licensing deal oncology pivot oncology portfolio oncology therapeutics oncolytic immunotherapy online program ontunisertib open science open-source AI open-source dataset openFDA operating profit margin operational efficiency operational transformation ophthalmic preparation optimisation programme opto-acoustic imaging oral FASN oral PCSK9 oral asthma therapy oral carbapenem oral cholesterol pill oral drugs oral formulations oral inhibitors oral obesity drug oral peptide oral peptides oral pill vaccine oral regimen oral small-molecule therapeutics oral small-molecule therapy oral weight loss drug orchestration orelabrtuinib orexin agonist organ donor organic growth orglipron orphan drug exclusion orthopedic innovation osavampator ossificans otoferlin out-licensing overall response rate overcapacity overhaul overhype overmedicalization overseas oversubscribed fund ownership increase ozekibart ozureprubart p-tau217 p300/CBP inhibitor p53 reactivator packaging issues pain crises palivizumab pamirtecan pan-JAK inhibitor pan-KRAS pandemic influenza partial response partnering with partnership termination pasritamig patent cliffs patent expiration patent license patented drugs patient management patient navigation patient-specific therapies patient-specific therapy patritumab pattern hair loss pause recommendation payer paying payload peak sales pediatric brain cancer pediatric drug designation pelareorep penicillin recall persevERA personal data personal genome service personalized cancer therapy personalized care personalized health services personalized healthcare personalized neuromodulation personnel change perspectives pertuzumab petition pharma TV ads pharma companies pharma division pharma industry pharma innovation pharma investments pharma packaging pharma patent expirations pharma policy pharma response pharma tech pharma trade group pharmaceutical advertising crackdown pharmaceutical backing pharmaceutical collaboration pharmaceutical commercialization pharmaceutical communications pharmaceutical delays pharmaceutical divestment pharmaceutical employment pharmaceutical imports pharmaceutical lawsuits pharmaceutical licensing pharmaceutical market pharmaceutical mergers pharmaceutical milestones pharmaceutical partnership pharmaceutical rebates pharmaceutical revenue pharmaceutical setback pharmaceutical setbacks pharmaceutical trade war pharmacy platform pharmacy reimbursement phase 3 failure philanthropy phosphodiesterase 4B pimecrolimus pipeline cull pipeline gaps pipeline management pipeline restructuring pipeline setbacks pipeline shake-up pipeline shift pipeline update pituitary adenylate cyclase activating polypeptide pivot resources pizuglanstat plant construction plasma-derived therapy platelet levels platform immunotherapy * * platinum-resistant pledge pneumococcal conjugate vaccines point-of-care political poly-N-4-vinylbenzyllactonamide portfolio companies portfolio prioritization portfolio reprioritization portfolio support posdinemab post-COVID post-marketing requirement postprandial povetacicept povorcitinib pozdeutinurad practice-changing pre-IPO ' pre-funded precision cancer precision neurology preclinical CRO preclinical drug preclinical pipeline preclinical program preclinical research predictive predictive models pregnancy detection pregnancy screening preliminary injunction premium prepulse inhibition activity presbyopia prescribers prescribing habits prescription discounts prescription drug ads prespecified pretomanid preventive services panel price controls price decline price hike price transparency pricing pressures prioritization priority review vouchers private block trade private placement proactive care product product hopping profit margin profitability programmable RNA medicines programmable biology progressiva project cancellation propane propiolactone protections protein compounds protein design protein drug discovery protein elimination therapeutics protein folding protein levels protein science protein-based vaccine protein-ligand datasets protein-ligand prediction protocol design provider operations pseudobulbar psychedelic medicine psychedelic supply psychiatric trials psychiatry pipeline public biotech public companies public company public health agencies public health crisis public health debate public health guidance public health leaders public servants pure-play strategy quality assurance quality control violations quantum phenomena questions radical transparency radiographic remission radiological imaging radiotheranostics radiotherapeutic radiprodil ranibizumab rare blood disorder rare disease ras Oncogene reSET (device) real-estate real-time real-time disclosure real-time publishing realistic medical scenarios rebate rate rebate schemes rebound rebranding reciprocal tariffs recombinase recombinational repair recurrence-free survival recurrent astrocytoma redesable eye drop reduction in force reform reforms refusal-to-file regulatory AI frameworks regulatory RNA regulatory advocacy regulatory alignment regulatory barriers regulatory certainty regulatory challenges regulatory change regulatory changes regulatory complexity regulatory consulting regulatory decision regulatory disclosure regulatory dynamics regulatory governance regulatory harmonization regulatory hurdle regulatory hurdles regulatory innovation regulatory law regulatory meetings regulatory policy regulatory reform regulatory reforms regulatory setback regulatory standards regulatory streamlining regulatory transparency reinstatement relacorilant relapsed/refractory large-B-cell lymphoma relapsed/refractory multiple myeloma relatlimab remote scanning remternetug renal response renewal representatives reproductive health biotech reproxalap repurchase reputation requirements rescheduling rese-cel research discontinuation research instrument development research partnerships research retraction research study research universities resignations resource shortage respiratory vaccines respiratory virus season restraining order restricted population restructuring charges resume analysis revakinagene taroretcel-lwey revamp revenue dip revenue target reverse merger revumenib revyve rezpegaldesleukin ribonucleoside-diphosphate reductase activity rilvegostomig risk-based oversight risperidone risvodetinib robotic HIFU robotic automation robotic knee replacement roll-ups romantasy ' rondecabtagene autoleucel roundtable royalty acquisition royalty management royalty monetization rubrics sacituzumab tirumotecan safety signal salanersen sale rule sales growth sales guidance salicylhydroxamic acid sample stabilization satralizumab scPharmaceuticals scale-up scenario science-led storytelling scientific discovery scientist protest scrutiny search - EntityNameUse seasonal flu secondary blood cancers secondary markets sector rotation secured secured debt securities fraud seed financing seed investments seizure drug seladelpar self-administered drug self-administration self-collection devices self-injectable self-injection business self-injection systems self-paying self-serve self-service semiconductor supply chains semiconductor tariffs sensor (device) sequence-based AI serono setback setmelanotide setrusumab seventh sham surgery sham-controlled trial shareholder value shortage shrinking budgets shutdowns shuttles sigma-2 receptor single-dose vials sirolimus site closures site transfer skin clearance skinny label sleep biotech small molecule agonists small molecule candidates small molecule drug discovery small molecule drugs small molecule inhibitors small molecule medicines small molecule therapies small molecule therapy social disadvantage solid cancers solid-state batteries soquelitinib sorfequiline sotatercept-csrk sotorasib spatial profiling spatial proteomics spesolimab spin-out spinoff spotty complaint reporting staff exclusion staff reduction staff reorganization stage IV reduction stake stake sale stance standards characteristics stealth stem cell-derived islet cells stem cell-secreted proteins sterile cartridge facility sterile manufacturing steroid-sparing stock plunge stock price stock purchase stock repurchase programs stock sale stock sales stock slip stockholder stockpile stockpiling strain selection strategic advisory strategic alignment strategic collaborations strategic decision-making strategic investors strategic options strategic overhaul strategic pivot strategic plan strategic reserves strategic transformation strategy streamlined process streamlined review stroke trial subcutaneous administration subcutaneous delivery sublingual tablets submission delays submission program succession planning suicide warnings sunitinib superbugs supercomputer superiority trials supply chain exposure supply chain management supply chain resilience supply chains supply shortages supply suspension suppurativa surgical planning surrogate endpoint surveillance aspects survival data survival rate suvorexant synovial fibroblasts synthetic construct synthetic royalty syphilis treatment tafamidis target-effector pairs targeted alpha therapy tariff avoidance tariff exemptions tariff increase tariff pause tariff threat tarlatamab-dlle tau-targeting tau-targeting antibody tazemetostat team transformation tech partnerships technology innovation teen suicide tenofovir tenofovir disoproxil fumarate terminated - RoleStatus therapeutic areas therapeutic development therapeutic diversification therapeutic payloads theta/beta ratio three-year thrombotic disease thymic stromal lymphopoietin thymus regeneration thymus-targeted thymus-targeted therapy ties time acceleration tissue models tividenofusp tobevibart top-selling drugs topical amitriptyline topical treatment topline total health trade agreement trade compliance trade deficit trade deficits trade policy trading trans-splicing ribozyme transatlantic trade transdermal cannabidiol gel trauma qualifier traveler treatment approval treatment discontinuations treatment prediction treatment resistance treatment-resistant hypertension trial failure trial site irregularities triple hormone receptor agonist triple seronegative triple therapy trispecific antibody tumor response tumor shrinkage tumor targeting tumor-specific antigens turbulence turnaround strategy twice-yearly type I uUTIs ultra-long acting ultra-rare diseases ultra-short regimen unanimous vote underwritten unicorn startup university lawsuit unmet unreliable upfront cash upfront discounts upgrade upheaval urgent care visits urothelial cancer ursodiol utilization qualifier uveal melanoma uveitic macular edema vIGA-AD vaccine advisors vaccine advisory panel vaccine alternatives vaccine approval vaccine framework vaccine guidelines vaccine industry vaccine injuries vaccine licensing vaccine misinformation vaccine oversight vaccine panel vaccine pipeline vaccine programs vaccine regulation vaccine sales vaccine skepticism vaccine standards vaccine trial valbenazine valley of death value maximization value-based pricing valve disease varegacestat vascular deposit binding vascular intelligence vascular intervention vascular leakage vector vectorized veligrotug vendor-agnostic verekitug vial stopper defects vidofludimus vilobelimab violation viral shedding viral suppression vision improvement vobra vomiting prevention vorolanib vote voting voucher program vusolimogene oderparepvec waveLINE-003 wear time wearable biosensor wearable regulations wearable sensors wearable technology healthcare wearables market web navigation webinar calendar webinars weight loss business weight loss data weight loss maintenance weight loss market weight loss medication weight loss therapy weight maintenance weight regain weight-loss wellness apps * * wet AMD white glove delivery whole-virus wild-type wind-down operations workflow automation workforce workforce termination workplace toxicity world 's wound care z-rostudirsen zasocitinib zelicapavir zetomipzomib ziclumeran zidesamtinib zoliflodacin zolucatetide zongertinib zopapogene imadenovec-drba Élancé

Show more Show less

Powered by Blogger

X-Data LLC